



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/16, 47/12		A1	(11) International Publication Number: WO 96/33699 (43) International Publication Date: 31 October 1996 (31.10.96)
(21) International Application Number: PCT/US96/06502		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 29 April 1996 (29.04.96)		Published <i>With international search report.</i>	
(30) Priority Data: 08/430,491 28 April 1995 (28.04.95) US			
(60) Parent Application or Grant (63) Related by Continuation US Filed on 08/430,491 (CIP) 28 April 1995 (28.04.95)			
(71) Applicant (for all designated States except US): EMISPHERE TECHNOLOGIES, INC. [US/US]; 15 Skyline Drive, Hawthorne, NY 10532 (US).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): MILSTEIN, Sam, J. [US/US]; 1 Knollwood Drive, Larchmont, NY 10538 (US).			
(74) Agents: ROBINSON, Joseph, R. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022 (US).			

(54) Title: DIAMIDE-DICARBOXYLIC ACID MICROSPHERES

(57) Abstract

Diamide-dicarboxylic acid microspheres are provided. The diamide-dicarboxylic acids may be combined with active agent(s). The resultant composition may be in microsphere form. Also disclosed are methods for administering the microsphere and/or composition that includes the active agent. The microsphere, with or without active agent, may be prepared by (A) solubilizing, in a solvent, at least one diamide-dicarboxylic acid, to yield a first solution; and (B) contacting the first solution with a precipitator solution in which the diamide-carboxylic acid is insoluble and optionally with an active agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

10

DIAMIDE-DICARBOXYLIC
ACID MICROSPHERES

This is a Continuation-in-Part of U.S. Patent Application Serial No. 08/430,491 filed on April 28, 1995.

15 **FIELD OF THE INVENTION**

The present invention relates to compositions and preferably microspheric compositions prepared from diamide-dicarboxylic acids, esters thereof, or diesters thereof. These compositions are useful in the delivery of a cargo to a target, and particularly in the oral delivery of biologically or 20 chemically active agents. Methods for the preparation and for the administration of such compositions are also disclosed.

BACKGROUND OF THE INVENTION

Conventional means for delivering active agents to their intended 25 targets, such as human organs, tumor sites, etc., are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, the environment of the target for delivery, or the target itself.

Biologically active agents are particularly vulnerable to such 30 barriers. Oral delivery to the circulatory system would be the route of choice for administration of many active agents to animals if not for physical barriers such as the skin, lipid bilayers, and various organ membranes that are relatively impermeable to certain biologically active agents, but which must be traversed before an agent delivered via the oral route can reach the

circulatory system. Additionally, oral delivery is impeded by chemical barriers such as the varying pH of the gastro-intestinal tract and the presence of powerful digestive enzymes.

- Earlier methods for orally administering vulnerable
- 5 pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitors,
- 10 diisopropylfluorophosphate (DFF) and trasyloL) to inhibit enzymatic degradation.

- Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Patent No. 4,239,754; Patel et al. (1976), *FEBS Letters*, Vol. 62, pg. 60; and Hashimoto et al. (1979),
- 15 *Endocrinology Japan*, Vol. 26, pg. 337.

- However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life;
- 20 (4) the systems are difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.

- More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For
- 25 example, U.S. Patent No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.

- Further studies have demonstrated that cyclic peptides with an even number of alternating L- and D-amino acids were able to form organic nanotubes. (See, Whitesides et al., *Science* 1991, 254, 1312, 1319; Ghadiri, M.R. et al., *Nature* 1993, 366, 324-327.) Additionally, stabilized spherical micelles and tubular vesicles have been prepared from amphiphiles and

bolamphiphiles. (See, Fuhrhop, J.H. et al., *J. Amer. Chem. Soc.*, 1991, 113, 7437, 7439; Frankel, D.A. et al. *J. Amer. Chem. Soc.*, 1991, 113, 7436, 7437; Fuhrhop, J.H. et al., *J. Amer. Chem. Soc.*, 1993, 115, 1600-1601.) L-Asp-diketopiperazines appended with amino acid subunits were found to

- 5 self assemble into microspheres by Bergeron et al., *J. Amer. Chem. Soc.* (1994) 116:8479-8484. This self assembly process was sensitive to solution pH and substrate concentration.


However, there is still a need in the art for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad

- 10 range of active agents.

SUMMARY OF THE INVENTION

The present invention discloses microspheres comprising diamide-dicarboxylic acids having the formula

15



20

wherein:

- R is C₁-C₂₄ alkyl, C₁-C₂₄ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl, phenyl, naphthyl, (C₁-C₁₀ alkyl) phenyl, (C₁-C₁₀ alkenyl) phenyl, (C₁-C₁₀ alkyl) naphthyl, (C₁-C₁₀ alkenyl) naphthyl, phenyl (C₁-C₁₀ alkyl), phenyl 25 (C₁-C₁₀ alkenyl), naphthyl (C₁-C₁₀ alkyl), or naphthyl (C₁-C₁₀ alkenyl);

optionally R may be substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, C₁-C₄ alkoxy, -OH, -SH, -CO₂R¹, or any combination thereof;

R¹ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkenyl; R is optionally interrupted by oxygen, nitrogen, sulfur, or any combination thereof;

- 30 n is 0 or 1; and

A and B independently are an amino acid radical or a poly amino acid radical;

an ester thereof, a diester thereof, or any combination of any of the foregoing.

The diamide-dicarboxylic acids of the present invention may be combined with active agent(s). The resultant composition may be in microsphere form.

- Also contemplated are methods for administering the
- 5 microsphere and/or composition that includes the active agent. In an alternate embodiment, the microsphere, with or without active agent, is prepared by
- (A) solubilizing, in a solvent, at least one diamide-dicarboxylic acid of Formula I above, to yield a first solution; and
- 10 (B) contacting the first solution with a precipitator solution and optionally an active agent, in which the diamide-dicarboxylic acid is insoluble.

BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1 is an illustration of the reaction scheme for the preparation of several of the diamide-dicarboxylic acids useful in the preparation of microspheres and compositions according to the present invention.

20 Figure 2 is an illustration of the reaction scheme for the preparation of several of the diamide-dicarboxylic acids useful in the preparation of microspheres and compositions according to the present invention.

25 Figure 3 is an illustration of the reaction scheme for the preparation of several of the diamide-dicarboxylic acids useful in the preparation of microspheres and compositions according to the present invention.

30 Figure 4 is an illustration of the reaction scheme for the preparation of several of the diamide-dicarboxylic acids useful in the preparation of microspheres and compositions according to the present invention.

Figures 5a, 5b, 5c and 5d are SEM micrographs of microspheres prepared according to the present invention.

Figure 6 is a TEM micrograph of microspheres prepared according to the present invention.

Figures 7 and 8 are graphic illustrations of the transmittance v. concentration of microspheres according to the present invention.

5 Figures 9 and 10 are graphic illustrations of the transmittance v. pH of microspheres according to the present invention.

Figure 11A is a computer generated illustration of the structure of the diamide-dicarboxylic acid from Example 4.

10 Figure 11B is a computer generated illustration of the structure of the diamide-dicarboxylic acid from Example 15.

Figure 12 is an illustration of the intramolecular hydrogen bonding patterns available from adipamide and cyclohexyl diamide diacids from Example 23.

15 Figure 13 is an illustration of the association of helical diacids.

Figure 14A is a computer generated illustration of the structure of a diamide-dicarboxylic acid from Example 8.

Figure 14B is a computer generated illustration of the structure of a diamide-dicarboxylic acid from Example 12.

20 Figure 14C is a computer generated illustration of the structure of a diamide-dicarboxylic acid from Example 16.


Figures 15A, 15B, and 15C are ^1H NMR spectra of the diamide-dicarboxylic acid from Example 23b, in d_6 -DMSO (15A), d_4 -Methanol (15B) and d_6 -Acetone (15B).

25 Figure 16 is a ^1H NMR spectrum of the diamide-dicarboxylic acid from Example 23b, in a ten percent deuterated water solution.

DETAILED DESCRIPTION OF THE INVENTION

Diamide-Dicarboxylic Acids

The diamide-dicarboxylic acids useful in the present invention are 30 of the formula



wherein

RECTIFIED SHEET (RULE 91)

R is C₁-C₂₄ alkyl, C₁-C₂₄ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl, phenyl, naphthyl, (C₁-C₁₀ alkyl) phenyl, (C₁-C₁₀ alkenyl) phenyl, (C₁-C₁₀ alkyl) naphthyl, (C₁-C₁₀ alkenyl) naphthyl, phenyl (C₁-C₁₀ alkyl), phenyl (C₁-C₁₀ alkenyl), naphthyl (C₁-C₁₀ alkyl), or naphthyl (C₁-C₁₀ alkenyl);

5 optionally R may be substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl, C₁-C₄ alkoxy, -OH, -SH, -CO₂R¹, or any combination thereof;

R¹ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkenyl; R is optionally interrupted by oxygen, nitrogen, sulfur, or any combination thereof;

n is 0 or 1; and

10 A and B independently are an amino acid radical or a poly amino acid radicals.

Preferably A and B are the same amino acid radical and n is 0.

When A and B are the same, the diamide-dicarboxylic acid is a bis-amide dicarboxylic acid. Esters and diesters of the diamide-dicarboxylic acids are

15 also suitable for microsphere preparation.

The phrase interrupted by oxygen, nitrogen, sulfur, or any combination thereof, means that the R groups can have one or more hetero-atoms inserted at one or more positions in the R group chain or ring. For example, non-limiting interruptions could be those that form ether, amine, and thioether, linkages and heterocyclic rings.

An amino acid is any carboxylic acid having at least one free amine group and includes naturally occurring and synthetic amino acids. An amino acid radical is a amino acid in which one hydrogen atom of a free amine group has been removed such as by, for example, a condensation


25 reaction in the formation of the diamide-dicarboxylic acid.

Amino acid radicals are derived from naturally occurring or synthetic amino acids. Amino acid radicals are preferably derived from α -amino acids, and most preferably from naturally occurring α -amino acids.

Many amino acids and amino acid esters are readily available from a number 30 of commercial sources such as Aldrich Chemical Co. (Milwaukee, WI, USA); Sigma Chemical Co. (St. Louis, MO, USA); and Fluka Chemical Corp (Ronkonkoma, N.Y. USA).

Representative, but not limiting, amino acids from which amino acid radicals suitable for use in the present invention may be derived are generally of the formula

5



wherein: R^3 is hydrogen, $\text{C}_1\text{-}\text{C}_4$ alkyl, or $\text{C}_2\text{-}\text{C}_4$ alkenyl;

10 R^4 is $\text{C}_1\text{-}\text{C}_{24}$ alkyl, $\text{C}_2\text{-}\text{C}_{24}$ alkenyl, $\text{C}_3\text{-}\text{C}_{10}$ cycloalkyl, $\text{C}_3\text{-}\text{C}_{10}$ cycloalkenyl, phenyl, naphthyl, ($\text{C}_1\text{-}\text{C}_{10}$ alkyl) phenyl, ($\text{C}_2\text{-}\text{C}_{10}$ alkenyl) phenyl, ($\text{C}_1\text{-}\text{C}_{10}$ alkyl) naphthyl, ($\text{C}_2\text{-}\text{C}_{10}$ alkenyl) naphthyl, phenyl ($\text{C}_1\text{-}\text{C}_{10}$ alkyl), phenyl ($\text{C}_2\text{-}\text{C}_{10}$ alkenyl), naphthyl ($\text{C}_1\text{-}\text{C}_{10}$ alkyl), or naphthyl ($\text{C}_2\text{-}\text{C}_{10}$ alkenyl);

15 R^4 being optionally substituted with $\text{C}_1\text{-}\text{C}_4$ alkyl, $\text{C}_2\text{-}\text{C}_4$ alkenyl, $\text{C}_1\text{-}\text{C}_4$ alkoxy, $-\text{OH}$, $-\text{SH}$, $-\text{CO}_2\text{R}^5$, $\text{C}_3\text{-}\text{C}_{10}$ cycloalkyl, $\text{C}_3\text{-}\text{C}_{10}$ cycloalkenyl, heterocycle having 3-10 ring atoms wherein the hetero atom is one or more of N, O, S, or any combination thereof, aryl, ($\text{C}_1\text{-}\text{C}_{10}$ alkyl)aryl, ar($\text{C}_1\text{-}\text{C}_{10}$ alkyl) or any combination thereof;

20 R^4 being optionally interrupted by oxygen, nitrogen, sulfur, or any combination thereof; and

R^5 is hydrogen, $\text{C}_1\text{-}\text{C}_4$ alkyl, or $\text{C}_2\text{-}\text{C}_4$ alkenyl.

The preferred naturally occurring amino acids are alanine,

25 arginine, asparagine, aspartic acid, citrulline, cysteine, cystine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, hydroxy proline, γ -carboxyglutamate, phenylglycine, or O-phosphoserine. The preferred amino acids are arginine, leucine, lysine, phenylalanine, tyrosine, 30 tryptophan, valine, and phenylglycine.

The preferred non-naturally occurring amino acids are β -alanine, α -amino butyric acid, γ -amino butyric acid, γ -(aminophenyl) butyric acid, α -amino isobutyric acid, citrulline, ϵ -amino caproic acid, 7-amino heptanoic acid, β -aspartic acid, aminobenzoic acid, aminophenyl acetic acid,

aminophenyl butyric acid, γ -glutamic acid, cysteine (ACM), ϵ -lysine, ϵ -lysine (A-Fmoc), methionine sulfone, norleucine, norvaline, ornithine, d-ornithine, p-nitro-phenylalanine, hydroxy proline, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, and thioproline.

- 5 Poly amino acids are either peptides or two or more amino acids linked by a bond formed by other groups which can be linked, e.g., an ester, anhydride or an anhydride linkage. Poly amino acids can be homo- or hetero-poly amino acids, and can include natural amino acids, synthetic amino acids, or any combination thereof. Poly amino acids can be homo- or hetero- poly
10 amino acids, and can include natural amino acids, synthetic amino acids, or any combination thereof.

Peptides are two or more amino acids joined by a peptide bond. Peptides can vary in length from di-peptides with two amino acids to polypeptides with several hundred amino acids. See, Walker, Chambers

- 15 Biological Dictionary, Cambridge, England: Chambers Cambridge, 1989, page 215. Poly amino acid radicals are poly amino acids in which at least one, and preferably one, hydrogen atom of a free amine group has been removed such as by, for example, a condensation reaction in the formation of the diamide-dicarboxylic acid.

20

Active Agents

- Active agents suitable for use in the present invention include biologically active agents and chemically active agents, including, but not limited to, fragrances, as well as other active agents such as, for example,
25 cosmetics.

- Biologically active agents include, but are not limited to, pesticides, pharmacological agents, and therapeutic agents. For example, biologically active agents suitable for use in the present invention include, but are not limited to, peptides, and particularly small peptides; hormones, and
30 particularly hormones which by themselves do not or only pass slowly through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro-intestinal tract; polysaccharides, and particularly mixtures of muco-polysaccharides; carbohydrates; lipids; or

- any combination thereof. Further examples include, but are not limited to, human growth hormones; bovine growth hormones; growth releasing hormones; interferons; interleukin-1; insulin; heparin, and particularly low molecular weight heparin; calcitonin; erythropoietin; atrial natriuretic factor;
- 5 antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO); anti-microbials, including, but not limited to anti-fungal agents; or any combination thereof.

10 The methods and compositions of the present invention may combine one or more active agents.

Microspheres

- The diamide-dicarboxylic acids as well as the compositions that
- 15 include active agent(s) of the present invention may be assembled into microspheric forms. Microspheres can generally be of the matrix form or the microcapsule form. The matrix form includes both a hollow matrix sphere in which the diamide-dicarboxylic acid forms a matrix shell and a hollow center and the optional active agent is distributed throughout the matrix, as well as
- 20 a solid matrix sphere in which the diamide-dicarboxylic acid forms a spherical continuum in which the optional active agent is distributed.

The microcapsule form is one in which the diamide-dicarboxylic acid forms a shell around a hollow core which can encapsulate an active agent. The encapsulated active agent can be in solution or can be a solid.

- 25 Preferably, the diamide-dicarboxylic acid which forms a microsphere will be able to form microspheres in aqueous as well as organic solvents, and will yield microspheres in a narrow particle size distribution.

The particle size of a microsphere can aid in the efficient delivery of the sphere itself or an active agent to a target. Typically, microspheres of

30 the present invention will have a diameter of less than 10 μm , preferably in the range of from about 0.1 μm to about 10 μm , and most preferably, in the range of from about 0.2 μm to about μm .

The microspheres of the present invention are pharmacologically harmless. They do not effectively impair the active (i.e. biological, chemical, therapeutical, pharmacological, or the like) agent.

Microspheres which are targeted to an acidic environment can

- 5 be made selectively soluble at acidic pH, such as the pH in the stomach. These compositions are prepared with an acid-soluble diamide-dicarboxylic acid. The acid-soluble diamide-dicarboxylic acid exists largely in the cation form in at least a portion of the pH range from about 1 to about 6.8. However, above about 6.8 or at selected ranges above pH 6.8, the diamide-
- 10 dicarboxylic acid is largely unprotonated and insoluble in water. Therefore, the carrier could self assemble to microspheres at basic or neutral pH, and any active agent in the delivery composition would not be released until the diamide-dicarboxylic acid solubilizes upon encountering an acidic pH.

Microspheres which are to be targeted to an alkaline

- 15 environment can be made selectively soluble at alkaline pH, such as the pH in the distal portion of the intestine. These compositions are prepared with a base-soluble diamide- dicarboxylic acid. The base-soluble diamide-dicarboxylic acid exists largely in an anionic form in at least a portion of the pH range of from about 7.2 to about 11. However, below and at pH 7.2, the
- 20 carrier is largely protonated and insoluble in water. Therefore, the diamide-dicarboxylic acid could self assemble to microspheres at acidic or neutral pH, and the active agent in the delivery composition would not be released until the carrier solubilizes upon encountering a basic pH.

Microspheres which are targeted to a neutral environment can

- 25 be made selectively soluble at neutral pH. These compositions are prepared with a neutral-soluble diamide-dicarboxylic acid. The neutral-soluble diamide-dicarboxylic acid exists largely in a neutral form at neutral pH, i.e. from about 6.8 to about 7.2. However, above or below this range, the diamide-dicarboxylic acid is insoluble in water. Therefore, the diamide-dicarboxylic
- 30 acid could self assemble to microspheres at acidic or basic pH, and any active agent in the delivery composition would not be released until the diamide-dicarboxylic acid solubilizes upon encountering a neutral pH.

In a typical formulation, the final solution can contain from about 10 mg to about 2000 mg of diamide-dicarboxylic acid per ml of solution, preferably between about 20 to about 500 mg of diamide-dicarboxylic acid per ml of solution, and most preferably from about 20 to about 200 mg per 5 ml. Optionally, the mixture is heated to a temperature between about 20° C and about 60° C, preferably about 40° C, until the diamide-dicarboxylic acid dissolves. Particulates remaining in the solution may be filtered out by conventional means such as gravity filtration over filter paper. The diamide-dicarboxylic acid solution usually is maintained at the elevated temperature 10 and is mixed with any active agent and a precipitator, for example, an acid solution such as, for example, aqueous acetic or citric acid at a concentration ranging from about 1N to about 3N for acid insoluble diamide-dicarboxylic acids, a basic solution for base insoluble diamide-dicarboxylic acids, and a neutralizing solution for neutral insoluble diamide-dicarboxylic acids. The 15 active agent can be mixed with the precipitating solution or can be added separately. The resultant mixture is maintained for a period of time sufficient for microsphere formation as observed by light microscopy. Although it is preferred that the precipitating solution is added to the diamide-dicarboxylic acid solution, the diamide-dicarboxylic acid solution can be added to the 20 precipitating solution as well.

The solutions above may optionally contain additives such as stabilizing additives. The presence of such additives promotes the stability and dispersability of any active agent in solution. The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5% 25 (w/v), preferably about 0.5% (w/v). Suitable, but non-limiting examples of stabilizing additives include buffer salts, gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine. The preferred stabilizing agents are gum acacia, gelatin, and methyl cellulose.

The amount of active agent which may be encapsulated by the 30 microsphere is dependent upon a number of factors which include the concentration of agent in the encapsulating solution as well as the affinity of the agent for the diamide-dicarboxylic acid. The concentration of the active agent in the final formulation also will vary depending on the required dosage

of treatment. When necessary, the exact concentration can be determined by, for example, reverse phase HPLC analysis.

The size of the microspheres containing an active agent can be controlled by manipulating a variety of physical or chemical parameters, such

- 5 as the pH, osmolarity, ionic strength of the diamide-dicarboxylic acid solution, or size of the ions in solution, and/or by the choice of the precipitator used in the microsphere forming and loading process.

- For example, in the GI tract it is often desirable to use microspheres which are sufficiently small to deliver effectively the active
10 agent at the targeted area within the gastrointestinal tract. Small microspheres can also be administered parenterally by suspending the spheres in an appropriate carrier fluid (e.g. isotonic solution) and injecting the solution directly into the circulatory system, intramuscularly, or subcutaneously. The mode of administration of the delivery compositions
15 will vary, of course, depending upon the requirement of the active agent administered. It has been noted that large amino acid microspheres (greater than 50 μm) tend to be less effective as oral delivery systems.

Non-Microspheres

- 20 In an alternate embodiment, the diamide-dicarboxylic acids may be used directly as an active agent carrier by simply mixing one or more diamide-dicarboxylic acids, polyamino acids, or peptides with the active agent(s) prior to administration.

25 Further Formulations

The compositions of the present invention may be formulated into dosage units by the addition of one or more excipient(s), diluent(s), disintegrant(s), lubricant(s), plasticizer(s), colorant(s), or dosing vehicle(s). Preferred dosage unit forms are oral dosage unit forms. Most preferred



- 30 dosage unit forms include, but not limited to, tablets, capsules, or liquids. The dosage unit forms can include biologically, pharmacologically, therapeutically, or chemically effective amounts of the active agent or can include less than such an amount if multiple dosage unit forms are to be used

to administer a total dosage of the active agent. Dosage unit forms are prepared by methods conventional in the art.

Additives

5

The compositions of the present invention may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof. These compounds have the formulas below:



10


III

IV

Derivatives of these compounds are disclosed in U.S. Patent No. 5,206,384. Actinonin derivatives have the formula:

15

20



V

25 wherein R¹² is sulfoxymethyl or carboxyl or a substituted carboxy group selected from carboxamide, hydroxyaminocarbonyl and alkoxy carbonyl

groups; and R¹³ is hydroxyl, alkoxy, hydroxyamino or sulfoxyamino group. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.

5

Administration

- The compositions of the subject invention are useful for administering biologically active agents to any animals such as birds; mammals, such as primates and particularly humans; and insects. The system is particularly advantageous for delivering chemical or biologically active agents which would otherwise be destroyed or rendered less effective by conditions encountered before the microsphere reaches its target zone (i.e. the area in which the active agent of the delivery composition are to be released) and within the body of the animal to which they are administered. Particularly, the compositions of the present invention are useful in orally administering active agents, especially those which are not ordinarily orally deliverable.

- Additionally, microspheres without active agent are useful in contrast imaging, such as ultrasound imaging. The microspheres are administered to the subject. When the microspheres are present in the area to be examined, they provide necessary contrast.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following examples illustrate the invention without limitation.

25

All reagents were purchased either from the Aldrich Chemical Co. or the Sigma Chemical Co. and were used without further purification. Silica gel 40 mm, obtained from J.T. Baker, was used for flash column chromatography. ¹H NMR spectra were recorded at 300 MHz and ¹³C NMR were recorded at 75 MHz. Chemical shifts are given in parts per million

- 30 downfield from an internal tetramethylsilane standard. Mass spectra were carried out on a Kratos MS 80RFA or a Finnigan 4516 MS instrument. Optical rotations were run at 589 nm (the Na D-line) on a Perkin-Elmer 241 polarimeter, with c expressed as g of compound per 100 mL. Elemental

analyses were performed by Atlantic Microlabs, Norcross, GA. Melting points were uncorrected. Light microscopy was performed on a camera mounted-Zeiss light microscope. SEM micrographs were obtained on a Hitachi 4000 Scanning Electron Microscope and TEM micrographs were obtained on a 5 Hitachi 7000 Transmission Electron Microscope. Angles ϕ were estimated by modeling studies using a BIOSYM program (Biosym Technologies, 9685 Scranton, Road, San Diego, CA).

The modeling studies were conducted with BIOSYM software running on a Silicon Graphics Indigo2 workstation. The molecules were built 10 using standard amino acid templates, bond lengths, angles, and side chain dihedral angles. The atoms within each molecule were assigned their proper hybridization, charge and bond order utilizing the builder module of Insight (Version 2.3.1). The CVFF forcefield provided by the Discover module was chosen for the minimization constraints. This forcefield was applied to the 15 constructed peptide and evaluated with two methods (i.e. the steepest descent and conjugate gradient methods). The interaction number for the steepest descent method was 100 and 200 for the conjugate gradients method. The derivative (or convergence criterion) was chosen as 0.001 Kcal/mol- \AA . The conformational preference of each peptide was determined 20 in the following manner: the peptide underwent 1000 steps of a dynamic stimulation at 300 K with a time interval of 1.0 fs. The resulting lowest energy conformation was selected as the minima for this parameter set.

Example 1 - bis(N^o-amido-L-phenylalanine benzyl ester) malonate

25 L-phenylalanine benzyl ester (p-toluenesulfonate salt) (12.5 g, 29.2 mmol) was suspended in 100 ML CH₂Cl₂ and triethylamine (REA, 7.4 g, 73.1 mmol) was added. The resultant yellow solution was cooled to 0°C, and malonyl chloride (2.0 g:14.2 mmol) was added dropwise under a nitrogen atmosphere. After the addition was complete, the solution was warmed to 30 room temperature and stirred overnight. The resultant orange solution was washed successively with aqueous NaHCO₃, water, 1N HCl, and water again until the pH was 6. The organic layer was separated, dried over anhydrous MgSO₄, filtered, and concentrated to give an orange oil (6.2 g). Column

chromatography (40% ethyl acetate/hexane) gave the pure dibenzyl ester (1.92 g, 23%).

Properties are summarized below.

M.P. = 93-94°

5

^1H NMR (CDCl_3): δ 7.30 (m, 22H), 5.10 (q, 4H, CH_2), 4.88 (dd, 2H, CH), 3.13 (m, 6H, CH_2); Anal. Calcd. for $\text{C}_{35}\text{H}_{34}\text{N}_2\text{O}_6$: C 72.65, H 5.92, N 4.84, found C 72.49, H 5.91, N. 4.79. Optical rotation $[\alpha]\text{D}^{22} 19^\circ$ ($c = 0.5$, CHCl_3).

10 Example 2

bis(N₂-amido-L-phenylalanine benzyl ester) 1,1-dimethyl malonate

Dimethyl malonic acid (5.15 g, 39 mmol) and N-hydroxy succinimide (NHS, 9.58 g, 83 mmol) were dissolved in anhydrous tetrahydrofuran (THF, 150 mL). The resultant cloudy suspension was cooled to 0°C, and a solution of dicyclohexylcarbodiimide (DCC, 4.04 g, 19.6 mmol) in 75 mL of dry THF was added dropwise over 30 minutes. The ice bath was removed, and the solution was allowed to warm at room temperature and stirred overnight. The solution was filtered and concentrated. The crude N-hydroxy succinimide (NHS) ester was suspended in dry THF and cooled to 0°C. L-phenylalanine benzyl ester p-toluenesulfonate salt (34.2 g:80 mmol) was dissolved in CHCl_3 and was washed with aqueous NaHCO_3 . The organic layer was separated, dried over anhydrous MgSO_4 , filtered, and concentrated to give the free amine as an oil (19.0 g). The amine was dissolved in 50 mL dry THF and added dropwise to the cooled suspension. The reaction was warmed to room temperature and stirred overnight. The volatiles were removed under reduced pressure. The residue was dissolved in CDCl_3 and washed successively with 1N HCl, water, aqueous NaHCO_3 , and water. The organic layer was separated, dried over anhydrous MgSO_4 , filtered, and concentrated to give a yellow oil (20.5 g). Column chromatography (30% ethyl acetate/hexane, SiO_2 , $R_f = 0.37$) gave the pure ester (8.55 g, 36% overall).

Properties are summarized below.

5 ¹H NMR (CDCl₃): δ 7.30 (m, 16H), 7.02 (m, 6H), 5.15 (q, 4H, CH₂), 4.80 (dd, 2H, CH), 3.09 (m, 4H, CH₂), 1.32 (s, 6H, CH₃); Anal. Calcd. for C₃₇H₃₈N₂O₆: C 73.25, H 6.31, N 4.62, found C 73.21, H. 6.37, N. 4.57, Optical Rotation [α]D²²-9° (c = 0.5, CHCl₃).

Example 3bis(N-*α*-amido-L-phenylalanine t-butyl ester)1.1 cyclopropane dicarboxylate

10 1.1 cyclopropane dicarboxylic acid (3.24 g, 24.9 mmol) was reacted with DCC (11.3 g, 54.8 mmol) and NHS (6.31 g, 54.8 mmol) to give the crude bis NHS ester. The crude solid (9.0 g) was suspended in THF and was cooled to 0°C. L-phenylalanine t-butyl ester hydrochloride (14.07 g, 54.8 mmol) was converted to its free amine by the procedure of Example 2. The amine (13.36 g) was dissolved in dry THF and was added dropwise to 15 the cooled suspension of the NHS ester. After stirring overnight and workup, column chromatography (35% ethyl acetate/hexane, R_f=0.34) gave the pure di t-butyl ester.

Properties are summarized below.

20 (10.35 g, 77%), ¹H NMR (CDCl₃): δ 7.50 (d, 2H, NH) 7.20 (s, 10H, aromatic), 4.67 (dd, 2H, CH), 3.06 (d, 4H, CH₂), 1.40 (s, 18H, t-butyl), 1.23 (q, 4H, cyclopropyl); Anal. Calcd. for C₃₁H₄₀N₂O₆: C 69.38, H 7.51, N 5.22, found C 69.49, H 7.47, N 6.15. Optical Rotation [α]D²²48° (c - 1.7, CHCl₃).


25 Attempts to access these rather simple substrates by direct condensation of the geminal acids (1,1-dimethylmalonic acid and 1,1-cyclopropane dicarboxylic acid) with L-Phe esters using the Yamada reagent, diphenylphosphoryl azide (DPPA), yielded <10% of the desired bis-amides of Examples 2 and 3. The efficiency of this coupling (where R = Me or cyclo 30 CH₂) was improved substantially (up to 77% yield) by generating the bis-activated N-hydroxy succinimide (NHS) ester of the acids, prior to reaction with the respective L-Phe esters. Reaction of the NHS ester of the present malonic acid and L-Phe gave only a 5% yield of the bisamide of Example 1.

- For this reason, malonyl chloride was condensed with L-Phe benzyl ester to give the bis-amide of Example 1 in 23% yield. Subsequent deprotection of the terminal ester groups, either by hydrogenolysis of the benzyl ester (Haptung et al., *Org. React.*, VII, 263-326 (1953)) or by collapse of the *t*-butyl ester with trifluoroacetic acid (Bryan et al., *J. Amer. Chem. Soc.* 99:2353 (1977)) gave the free bis acids of Examples 4-6 in 74%, 74%, and 67% yield, respectively.
- 5 butyl ester with trifluoroacetic acid (Bryan et al., *J. Amer. Chem. Soc.* 99:2353 (1977)) gave the free bis acids of Examples 4-6 in 74%, 74%, and 67% yield, respectively.

Example 4bis(N α -amido-L-phenylalanine) malonate

- 10 The benzyl ester prepared according to the method of Example 1 (1.2 g; 2.07 mmol) was dissolved in MeOH (100 mL), and 10% Pd-C (0.35 g) was added. The black suspension was degassed three times, and hydrogen gas was introduced. After 2 hours, the catalyst was filtered off and was washed with MeOH. The filtrate was concentrated to give an oil (0.99 g). The crude product was purified by column chromatography (Sephadex LH-20, 15% EtOH/toluene) to give bis(N α -amido-L-phenylalanine)malonate as a white solid (0.61 g, 74%).
- 15 This reaction scheme is illustrated in Figure 1. Properties are summarized below.

- 20 M.P. = 162-164°C. ^1H NMR (CD_3OD): δ 7.22 (m, 10H, aromatic), 4.66 (dd, 2H, CH, J = 8 Hz), 2.99 (dd, 2H, diastereotopic CH_2 , J = 13.8 Hz, 8.1 Hz). Anal. Calcd. for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_6$: C 63.31; H 5.57; N 7.03. Found C 63.25; H 5.59; N 6.98. Optical Rotation $[\alpha]\text{D}^{22} 52^\circ$ (c = 0.3, estimated angle ϕ = 110°; MeOH).
- 25




wherein R_a = CHCH_2Ph , L-isomer;
 R_b = H; ϕ = 110°.

Example 5bis(N α -amido-L-phenylalanine) 1,1-dimethyl malonate

The method of Example 4 was followed, substituting the ester prepared according to the method of Example 2 (1.75 g, 2.88 mmol) for the 5 ester and stirring the reaction for 3 hours prior to work up. The crude solid (1.11 g) was purified by column chromatography (Sephadex LH-20, 15% EtOH/toluene) to give pure bis(N α -amido-L-phenylalanine) 1,1-dimethyl malonate as a white solid (0.91 g, 74%).

10 The reaction scheme is illustrated in Figure 1. Properties are summarized below.

M.P. = 62-64°C. ^1H NMR (CD_3OD): δ 7.20 (m, 10H, aromatic), 4.63 (m, 2H, CH), 3.25 (dd, 2H, CH_2) 3.01 (dd, 2H, CH_2 , 1.18 (s, 6H, CH_3); Anal. Calcd. for $\text{C}_{23}\text{H}_{26}\text{N}_2\text{O}_6$: C 64.78; H 6.14; N 6.57. Found C 64.67; H 6.20; N 6.46. Optical Rotation 15 $[\sigma]\text{D}^{22}-2^\circ$ (c = 1, MeOH). Estimated angle ϕ = 106°.



wherein $\text{R}_c = \text{CHCH}_2\text{Ph}$, L-isomer

20 $\text{R}_d = \text{CH}_3$; $\phi = 106^\circ$.

Example 6bis(N α -amido-L-phenylalanine) 1,1-cyclopropane dicarboxylate


The bis t-butyl ester prepared according to the procedure of 25 Example 3 (8.31 g, 15.5 mmol) was dissolved in CH_2Cl_2 (50 mL) and was cooled to 0°C.

Trifluoroacetic acid (TFA, 20 mL) was added dropwise under a nitrogen atmosphere. After 80 minutes, the volatiles were removed under reduced pressure to give a white solid. Column chromatography (Sephadex LH-20,

10% EtOH/toluene) gave the pure bis acid, bis (N_α-amide-L-phenylalanine) 1,1-cyclo propane dicarboxylic acid (4.4 g, 67%).

The reaction scheme is illustrated in Figure 1. Properties are summarized below.

- 5 ¹H NMR (d_6 -DMSO): δ 12.83 (br s, 2H, COOH), 8.49 (d, 2H, NH), 7.20 (m, 10H, aromatic), 4.42 (m, 2H, CH), 2.97 (m, 4H, CH₂), 1.18 (s, 4H, cyclopropyl); Anal. Calcd. for C₂₃H₂₄N₂O₆: C 65.08; H 5.70; N 6.60. Found C 65.15; H 5.79; N. 6.53. High resolution mass spectrum: theory 424.1634, found 424.1617.
- 10 Optical Rotation $[\alpha]D^{21}$ -3° (c = 1, MeOH). Estimated angle ϕ = 116°.



- 15 wherein R_e = CHCH₂Ph, L-isomer
R_f = cyclo CH₂; ϕ = 118°.

- These malonic derivatives of Examples 4-6 represent Phe diamides, which are separated by a single carbon spacer and whose relative angular orientation is fixed in space. For example, the angular orientation of the L-Phe amide pendants of malonic derivatives of Example 4 is fixed by the tetrahedral geometry of the central CH₂ spacer. In fact, the cisoid relationship (i.e. the amino acid pendants are oriented towards each other) imparted by the malonic backbone place the Phe groups as close as is possible in a *cis* diamide framework. While all of the malonamides have a single carbon spacer and this cisoid orientation of their Phe groups, the calculated angle between the amide carbonyls (defined here as ϕ) varies.
- The replacement of the hydrogen atoms on the central methylene of the compound of Example 4, with methyls (the compound of Example 5) or its incorporation into a cyclopropyl ring (the compound of

Example 6) allowed for perturbation of the angle ϕ , while keeping the spacer unit constant. The angle ϕ is decreased by the steric demands of geminal methyl groups in the compound of Example 5 and increased by the rehybridization requirements of the compound of Example 6.

5

Example 7bis(N α -amido-L-phenylalanine benzyl ester) oxalate

- Diphenyl phosphoryl azide (DPPA, 1.45 g, 5.25 mmol) was added dropwise at 0°C to a stirred solution of oxalic acid (.023 g, 2.5 mmol) and L-phenylalanine benzyl ester p-toluenesulfonate salt (2.14 g, 5 mmol) in 10 15 mL DMF. After 15 minutes, triethylamine (TEA, 1.1 g, 10 mmol) was added dropwise. The solution was allowed to warm to room temperature and was stirred overnight. Removal of the volatiles under reduced pressure, yielded an oil which was dissolved in CH₂Cl₂ and was washed successively with 1N HCl, water, aqueous NaHCO₃, and water again. The organic layer 15 was separated and was dried over anhydrous MgSO₄, filtered, and concentrated to give a pale yellow oil. The oil was recrystallized from 30% EtOAc/hexane to give the ester as a white solid (0.76 g, 54%).

Properties are summarized below.

M.P. = 158-159°C. ¹H NMR (CDCl₃): δ 7.20 (m, 20H), 5.42 (m, 2H), 5.10 (d, 2H), 4.93 (m, 4H), 2.96 (d, 4H); ¹³C NMR (CDCl₃) 172.4, 156.0, 135.8, 135.1, 129.4, 128.6, 128.5, 128.4, 128.3, 126.8, 67.1, 53.9, 38.5. Anal. Calcd. for C₃₄H₃₂N₂O₆:C 72.33, H 5.71, N 4.94, found C 72.56, H 5.96, N 5.10. Optical Rotation [α]D²⁵ 13° (c = 1, CHCl₃).

25


Example 8bis(N α -amido-L-phenylalanine) oxalate

- The method of Example 4 was followed substituting the ester prepared according to the procedure of Example 7 (0.56 g, 1 mmol) for the ester, 60 mg of -Pd-C, and stirring for 45 minutes prior to workup. Filtration 30 of the catalyst and concentration of the filtrate yielded bis(N α -amido-L-phenylalanine) oxalate as a white solid (0.38 g, 100%).

Properties are summarized below.

M.P. = 88-90°C. ^1H NMR (CD_3OD): δ 7.25 (m, 10H), 4.51 (m, 2H), 3.05 (m, 4H); ^{13}C NMR (d_6 -DMSO) 173.6, 156.8, 137.3, 128.1, 126.3, 53.9, 37.4. Anal Calcd. for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_6$: C 62.49, H 5.24, N 7.29, found C 62.14, H 5.46, N 7.60. Optical Rotation $[\alpha]\text{D}^{25} 46^\circ$ ($c = 1$, MeOH). Estimated angle $\phi = 180^\circ$.

5



10

 $R_g = \text{CHCH}_2\text{Ph}$, L-isomer $\phi = 180^\circ$.

The oxalic acid-bis(L-Phe) compound of Example 8 was synthesized in 54% overall yield by direct condensation of oxalic acid and L-Phe benzyl ester with DPPA to give benzyl ester of Example 7, followed by deprotection of the benzyl ester with H_2 over 10% Pd-C.

Example 9(N -amido-L-phenylalanine benzyl ester) mono succinate

4-methylmorpholine (1.12 mL, 12 mmol) was added dropwise at 20 0°C to a stirred solution of L-Phe benzyl ester, P-toluenesulfonate salt (2.14 g, 5 mmol) in 20 mL DMF and 20 mL THF. The resulting mixture was stirred for 30 minutes and succinic anhydride (0.5 g, 5 mmol) in 5 mL DMF was added. The reaction mixture was warmed to room temperature and was stirred overnight. The solvents were removed *in vacuo*. The resultant oil 25 was dissolved in EtOAc and washed with water. The organic layer was separated, dried over anhydrous MgSO_4 , filtered, and concentrated to give a white solid. Column chromatography (LH-20 Sephadex, 15% EtOH/toluene) provided the pure mono amide (1.2 g, 78%).

Properties are summarized below.

30

M.P. 108-109°C. ^1H NMR (CDCl_3): δ 9.00 (br, s, 1H), 7.05 (m, 10H), 6.30 (m, 1H), 5.10 (m, 2H), 4.91 (m, 1H), 3.07 (m, 2H),

2.63 (m, 2H), 2.45 (m, 2H); ^{13}C NMR (CDCl_3) 177.0, 171.3, 171.2, 135.4, 134.8, 129.2, 128.5, 127.0, 67.3, 53.2, 37.6, 30.3, 29.1. Anal. Calcd. for $\text{C}_{20}\text{H}_{21}\text{N}_1\text{O}_6$: C 67.59, H 5.96, N 3.94, found C 67.36, H 5.98, N 3.92. Optical Rotation $[\alpha]\text{D}^{28}-5^\circ$ (c = 1, MeOH).

Example 10bis(N α -amido-L-phenylalanine benzyl ester)
succinate

- BOP (0.93 g, 2.1 mmol) was added to a stirred solution of the
10 ester prepared according to the method of Example 9 (0.71 g, 2 mmol) and L-Phe benzyl ester, p-toluenesulfonate salt (0.90 g, 2.1 mmol) in 20 mL DMF cooled to 0°C. After stirring for 30 minutes, DIEA (0.54 g, 4.2 mmol) was added dropwise. The reaction mixture was warmed to room temperature and was stirred overnight. The volatiles were removed under reduced pressure.
15 The resulting oily residue was dissolved in ETOAc (100 mL) and washed with saturated aqueous NaHCO_3 , 30% citric acid, and water. The organic layer was separated, dried with Na_2SO_4 , and filtered. Upon removal of half of the solvent, the product precipitated out of solution as pure bis (N α -amido-L-phenylalanine benzyl ester) succinate (1.1 g, 93%).

20 Properties are summarized below.

M.P. 160-161°C. ^1H NMR (CDCl_3): δ 7.18 (m, 20H), 6.42 (d, 2H), 5.11 (q, 4H), 4.87 (m, 2H), 3.07 (M 4H); ^{13}C NMR (CDCl_3) 171.1, 170.9, 135.2, 128.8, 128.0, 126.5, 66.7, 52.9, 37.2, 30.8. Anal. Calcd. for $\text{C}_{36}\text{H}_{36}\text{N}_2\text{O}_6$: C 72.95, H 6.12, N 4.73,
25 found C 72.66, H 6.08, N 4.68. Optical Rotation $[\alpha]\text{D}^{28}23^\circ$ (c = 1, CHCl_3).

Example 11(N α -amido-L-phenylalanine) monosuccinate

- The method of Example 4 was followed substituting the ester
30 prepared according to the method of Example 9 (0.71 g, 2 mmol) for the ester, 100 mg of 10% Pd-C, and stirring for 6 hours prior to workup. Filtration of the catalyst and concentration of the filtrate gave a white solid. Column chromatography (LH-20 Sephadex, 10% EtOH/toluene) and

recrystallization with 50% EtOAc/hexane gave pure ($\text{N}\alpha$ -amido-L-phenylalanine)mono succinate (0.5 g, 94%).

This reaction scheme is illustrated in Figure 2. Properties are summarized below.

- 5 M.P. 104-105°C. ^1H NMR ($\text{CDCl}_3 + 10\%$ d_6 -DMSO): δ 8.02 (br s, 2H), 7.20 (m, 5H), 6.67 (d, 1H), 4.77 (m, 1H), 3.13 (m, 2H), 2.52 (m, 4H); ^{13}C NMR ($\text{CDCl}_3 + 1\%$ d_6 -DMSO) 174.8, 173.3, 171.7, 136.6, 129.6, 128.4, 126.9, 53.3, 37.5, 30.9, 29.6.
 10 Anal Calcd. for $\text{C}_{13}\text{H}_{15}\text{N}_1\text{O}_6$: C 60.22, H 5.85, N 5.01, found C 60.12, H 5.84, N 5.03. Optical Rotation $[\alpha]\text{D}^{25} 32^\circ$ ($c = 1$, MeOH).

Example 12

bis($\text{N}\alpha$ -amido-L-phenylalanine) succinate

- 15 The method of Example 4 was followed substituting the ester prepared according to the method of Example 10 (2.37 g, 4 mmol), for the ester, 0.2 g of 10% Pd-C, and stirring for 1 hour prior to workup. Filtration of the catalyst and concentration of the filtrate gave bis($\text{N}\alpha$ -amido-L-phenylalanine) succinate as a white solid (1.64 g, 99%). An analytical sample was obtained by recrystallization from a (1/1/1) solution of
 20 MeOH/EtOAc/hexane.

This reaction scheme is illustrated in Figure 2. Properties are summarized below.

- 25 M.P. 195-196°C. ^1H NMR (CD_3OD): δ 7.21 (m, 10H), 4.62 (m, 2H), 3.15 (m, 2H), 2.94 (m, 2H), 2.36 (m, 4H); ^{13}C NMR (CD_3OD) 175.1, 174.7, 138.8, 130.7, 129.8, 128.1, 55.5, 38.8, 32.4. Anal. Calcd. for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_6$: C 64.07, H 5.87, N 6.79, found C 64.08, H 5.85, N 6.76. Optical Rotation $[\alpha]\text{D}_{25} 27^\circ$ ($c = 1$, MeOH).

Example 13

bis($\text{N}\alpha$ -amido-L-phenylalanine t-butyl ester) maleate

L-phenylalanine t-butyl ester hydrochloride (2.21 g, 8.6 mmol) and maleic acid (0.46 g, 4 mmol) were combined in DMF (50 mL) and cooled to 0°C. BOP (3.95 g, 8.89 mmol) was added, and the solution was stirred

for 10 minutes. DIET (2.07 g, 16 mmol) was added dropwise over 10 minutes. The reaction was warmed to room temperature and was stirred overnight. The volatiles were removed under reduced pressure. The crude solid was dissolved in CH_2Cl_2 and was washed successively with 1N HCl,

- 5 water saturated NaHCO_3 , and water again. The organic layer was separated, dried over anhydrous MgSO_4 , filtered, and concentrated to give a yellow oil (3.77). Flash column chromatography (30% ethyl acetate/hexane, $R_f = 0.14$) gave the pure di-t-butyl ester (1.13 g, 54%).

Properties are summarized below.

- 10 M.P. 138-139°C. ^1H NMR (CDCl_3): δ 8.40 (d, 2H, NH), 7.18 (s, 10H, aromatic), 6.01 (s, 2H, olefinic), 4.73 (m, 2H CH), 3.10 (d, 4H, CH_2), 1.37 (s, 18H, t-butyl); Anal. Calcd. for $\text{C}_{30}\text{H}_{38}\text{N}_2\text{O}_6$: C 68.94, H 7.33, N 5.36, found C 68.88, H 7.40, N 5.30. Optical Rotation α_D^{21} 109° (c = 1.5, CDCl_3).

15

Example 14 bis(N α -amido-L-phenylalanine t-butyl ester) fumarate

- L-phenylalanine t-butyl ester hydrochloride (2.58 g, 10 mmol) and fumaric acid (0.58) g, 5 mmol) were combined in DMF (50 mL) and cooled to 0°C. BOP (4.42 g, 10 mmol) was added, and the solution was
20 stirred for 20 minutes. DIET (2.86 g, 22 mmol) was added dropwise over 10 minutes. The reaction was warmed to room temperature and was stirred overnight. The volatiles were removed under reduced pressure. The crude solid was dissolved in 50 mL EtOAc and was washed successively with 30% citric acid, water, saturated NaHCO_3 , and water again. The organic layer was
25 separated, dried over anhydrous MgSO_4 , filtered, and concentrated to give an oil (3.77 g). Flash column chromatography (40% ethyl acetate/ CHCl_3) gave the pure di-t-butyl ester (2.2 g, 84%).

Properties are summarized below.

- 30 M.P. 161-162°C. ^1H NMR (CDCl_3): δ 7.27 (m, 10H, aromatic), 6.96 (s, 2H, olefinic), 6.94 (d, 2H, NH), 4.91 (m, 2H, CH), 3.08 (d, 4H, CH_2), 1.47 (s, 18H, t-butyl); ^{13}C NMR (CDCl_3) 170.4, 163.5, 135.9, 133.0, 129.4, 128.3, 126.9, 82.5, 53.8, 37.8.
Anal. Calcd. for $\text{C}_{30}\text{H}_{38}\text{N}_2\text{O}_6$: C 68.94, H 7.33, N 5.36, found C

69.26, H 7.54, N 5.28. Optical Rotation $[\alpha]D^{20}$ -29° (c = 1, MeOH).

Example 15


bis(N α -amido-L-phenylalanine) maleate

- 5 The bis t-butyl ester prepared according to the method of Example 13 (1.03 g, 1.97 mmol) was cooled to 0°C, and TFA (20 mL) was added dropwise under a nitrogen atmosphere. After 1 hour, the volatiles were removed under reduced pressure to give a white solid. Column chromatography (6% EtOH/toluene then increased to 14% ETOH/toluene on 10 Sephadex LH-20) gave pure bis(N α -amido-L-phenylalanine)-maleate (0.80 g, 99%).

Properties are summarized below.

1H NMR (CD₃OD): δ 7.22 (m, 10H, aromatic), 6.18 (s, 2H, olefinic), 4.70 (dd, 2H, CH), 3.21 (dd, 2H, diastereotopic CH₂), 3.00 (dd, 2H, diastereotopic CH₂). Anal. Calcd. for C₂₂H₂₂N₂O₆: C 64.38, H 5.40, N 6.83, found C 64.53, H 5.59, N 6.65.

Optical Rotation $[\alpha]D^{21}$ 41° (c = 1, MeOH). Estimated angle ϕ = 60°.



20

R_h = CHCH₂Ph, L-isomer

ϕ = 60°.

25 Example 16

bis(N α -amido-L-phenylalanine) fumarate

The bis t-butyl ester prepared according to the method of Example 14 (1.04 g, 2.0 mmol) was cooled to 0°C, and TFA (25 mL) was added dropwise under a nitrogen atmosphere. After 1 hour, the volatiles were removed under reduced pressure to give a white solid. Recrystallization

from EtOAc/EtOH/hexane (1/1/1) gave pure bis (N α -amido-L-phenylalanine)-fumarate (0.73 g, 90%).

Properties are summarized below.

^1H NMR (CD₃OD): δ 7.08 (m, 10H) 6.68 (s, 2H), 4.56 (m, 2H, CH), 3.06 (m, 2H), 2.81 (dd, 2H), ^{13}C NMR (CD₃OD) 174.2, 166.3, 138.3, 133.7, 130.2, 129.4, 127.8, 55.4, 38.4, Anal. Calcd. for C₂₂H₂₂N₂O₆: C 64.38, H 5.40, N 6.83, found C 64.06, H 5.39, N 6.67. Optical Rotation $[\alpha]\text{D}^{28}$ 10° (c = 1, MeOH).

Estimated angle ϕ = 180°.

The succinic acid derivatives were synthesized stepwise by reaction of L-Phe benzyl ester and succinic anhydride. The mono amide acid of Example 9 was condensed with a second equivalent of L-Phe benzyl ester in the presence of BOP to give bis-amide of Example 10. Subsequent removal of the benzyl esters of these compounds by hydrogenation gave the mono(L-Phe) diacid of Example 11 and the bis (L-Phe) diacid of Example 12, respectively. DPPA promoted condensation of L-Phe t-butyl ester and maleic acid provided the bis amide of Example 13 in 11% yield. The coupling yield was improved significantly with the BOP reagent. Castro et al., *Tetrahedron Letters*, 1975, 1219; Castro et al., *Synthesis* 1976, 715. In this manner both the maleic diamide of Example 13 (54%) and the fumaric diamide of Example 14 (84%) were accessed. Treatment of the t-butyl esters of Examples 13 and 14 with TFA yielded the respective free acids of Examples 15 and 16 in 99% and 90% yield.

Example 17 - trans-1,2-(bis N α -L-phenylalanine benzyl ester)cyclohexane dicarboxylate.

To a well-stirred solution of (+)-*trans* -1,2-cyclohexane dicarboxylic acid (0.86g, 5.0 mmol) and L-phenylalanine benzyl ester p-toluenesulfonate salt (4.28g, 10.0 mmol) in DMF (50 mL) was added benzotriazoly-N-oxy-tris(dimethylamino)phosphoniumhexafluorophosphate (BOP, 4.42g, 10 mmol) at 0°C. The mixture was stirred for 20 minutes at 0°C and diisopropylethylamine (DIEA, 4.86g, 22.0 mmol) was added dropwise over a 5 minute period. The solution was allowed to warm slowly

to room temperature and stirred overnight. The volatiles were removed under reduced pressure and the residue was dissolved in 100 mL of CH_2Cl_2 . The organic layer was washed successively with 50 mL aliquots of H_2O , aq. citric acid, 10% NaHCO_3 , and H_2O . The organic layer was separated and dried over anhydrous MgSO_4 , filtered and concentrated to half volume. Upon standing a white solid precipitated from solution. This solid was filtered off to provide 17a, (0.7g). The filtrate was evaporated to dryness and the resulting solid chromatographed (10% EtOAc/ hexane) to provide 17b (0.8g) the diastereomer of 17a the total yield of 17a and 17b was 1.50g (47%).

5 Recrystallization of the above products from 15% EtOAc/ hexane provided analytical samples.

10

Properties are summarized below.

Diastereomer I 17a: M.P. 158-160°C. ^1H NMR (CDCl_3 , 7.26 (m, 16H), 6.96 (m, 4H), 6.21 (d, 2H), 5.15 (q, 4H), 4.78 (m, 2H), 3.06 (m, 4H), 2.38(m, 2H), 1.74 (m, 4H), 1.30 (m, 2H), 1.23 (m, 2H). ^{13}C NMR (CDCl_3) 174.4, 171.0, 135.8, 135.0, 129.3, 128.4, 126.8, 66.8, 53.1, 46.4, 37.6, 29.0, 24.7. Optical Rotation $[\alpha]_D^{28}$ 22° (c = 1, CHCl_3). Anal. Calcd. for $\text{C}_{40}\text{H}_{42}\text{N}_2\text{O}_6$: C 74.28, H 6.55, N 4.33, found C 74.01, H 6.51 N 4.34.

20 Diastereomer II 17b: M.P. 186-188°C. ^1H NMR (CDCl_3 , 7.26 (m, 16H), 7.03 (m, 4H), 6.10 (d, 2H), 5.08 (q, 4H), 4.86 (m, 2H), 3.00 (m, 4H), 2.46 (m, 2H), 1.80 (m, 4H), 1.35(m, 4H); ^{13}C NMR (CDCl_3) 174.4, 171.1 135.4, 135.0, 129.3, 128.4, 126.9, 67.0, 53.0, 46.5, 37.9, 29.4, 24.9. Optical Rotation $[\alpha]_D^{28}$ 25° (c = 1, CHCl_3). Anal. Calcd. for $\text{C}_{40}\text{H}_{42}\text{N}_2\text{O}_6$: C 74.27 H 6.55, N 4.33, Found C 74.13, H 6.57 N 4.34.

Example 18a - trans-1,2-bis(N α -L-phenylalanine) cyclohexane dicarboxylate.

30 The dibenzyl ester 17a (0.37g, 0.57 mmol) and 10% Pd-C (0.05g) were suspended in absolute MeOH (100 mL). The suspension was degassed three times and hydrogen gas introduced. The absorption of hydrogen ceased in 2h. TLC (15% EtOAc/ hexane) showed no starting

material remained after 15 min. The black suspension was filtered and the filtrate was concentrated to provide diastereomer acid I as a white solid (0.27g, 100%).

Properties are summarized below.

- 5 M.P. 202-203°C. ^1H NMR (CD₃OD) 7.26 (m, 10H), 4.62 (m, 2H), 3.13 (m, 4H), 2.44 (m, 2H), 1.71 (m, 4H), 1.25 (m, 4H), ^{13}C NMR (CD₃OD) 176.6, 174.1, 138.5, 130.5, 129.3, 127.6, 54.5, 47.1, 38.6, 30.8, 26.2. Optical Rotation $[\alpha]_D^{28}$ 65° (c = 1.0, MeOH). Anal. Calcd. for C₂₆H₃₀N₂O₆: C 66.94, H 6.48, N 6.01, Found C 66.78, H 6.51, N 5.99.
- 10

Example 18b

trans-1,2-bis(N α -L-phenylalanine) cyclohexane dicarboxylate.

- 15 The dibenzyl ester 17b (0.50g, 0.77 mmol) was combined with 10% Pd-C (0.05g) in degassed CH₃OH (100 mL) and H₂ gas introduced. After 1 hr the black suspension was filtered and the filtrate concentrated to give a white crystalline product 18b (0.36g, 100%).

Properties are summarized below.

- 20 M.P. 233-235°C. ^1H NMR (CD₃OD) 7.06 (m, 10H), 4.39 (m, 2H), 2.77 (m, 4H), 2.39 (m, 2H), 1.70 (m, 4H), 1.19 (m, 4H). ^{13}C NMR (CD₃OD) 177.2, 174.6, 138.1, 130.4, 129.3, 127.7, 55.0, 47.3, 38.4, 30.7, 26.3. Optical Rotation $[\alpha]_D^{28}$ 29° (c = 1.0, MeOH). Anal. Calcd. for C₂₆H₃₀N₂O₆: C 66.94, H 6.48, N 6.01, Found C 66.76, H 6.46, N 6.07.
- 25

Example 19

cis-1-carboxy-2-(N α -L-phenylalanine benzyl ester) cyclohexane carboxylate.

- To a well-stirred solution of cis-1,2-cyclohexane dicarboxylic anhydride (1.54g, 10.0 mmol) and L-phenylalanine benzyl ester-p-toluenesulfonate salt (4.28g, 10.0 mmol) in DMF (40 mL) was added 4-methylmorpholine (2.5 mL) dropwise at 0°C. The mixture was stirred and warmed to room temperature overnight. Evaporation under vacuum provided a white solid which was dissolved in CH₂Cl₂ (100 mL), washed with H₂O (4 x

40 mL) and dried over anhydrous MgSO₄ and filtered. Removal of the solvent from the filtrate provided a white powder. Column chromatography (40% EtOAc/ hexane) provided the mono amide acid (3.2g, 78%).

Properties are summarized below.

- 5 M.P. 107-108°C. ¹H NMR (CD₃OD) 7.16 (m, 10H), 6.23 (m, 1H) 5.10 (q, 2H), 4.92 (m, 1H), 3.10 (d, 2H), 2.81 (m, 2H), 2.00 (m, 2H), 2.60 (m, 6H). ¹³C NMR (CD₃OD) 177.8, 173.4, 171.0, 135.1, 128.8, 128.1, 126.5, 66.8, 52.6, 43.3, 42.1, 37.3, 26.4, 23.0. [α]_D²⁴ 20° (c = 1.0, CHCl₃). Anal. Calcd. for C₂₄H₂₆N₁O₆: C 70.57, H 6.42, N 3.43; Found C 70.42, H 6.48, N 3.49.
- 10

Example 20

cis-1,2-(bis Na-L-phenylalanine benzyl ester)
cyclohexane carboxylate,

- BOP (1.33g, 3.0 mmol) was added to a solution of 6 (1.22g, 15 3.0 mmol), L-phenylalanine benzyl ester p-toluenesulfonate salt (1.28g, 3.0 mmol) and DMF (50 mL) at 0°C. The mixture was stirred for 20 min. Diisopropylethylamine (DIEA, 2.71g, 21 mmol) was added dropwise. The resulting mixture was kept stirring and warmed to room temperature overnight. The volatiles were removed under reduced pressure and the 20 remaining oil dissolved in 100 mL of CH₂Cl₂, washed with 50 mL of H₂O, aq. citric acid, NaHCO₃ and H₂O, dried over anhydrous MgSO₄ and filtered. Evaporation of the filtrate followed by flash chromatography (40% EtOAc / hexane) gave the diamide dibenzyl ester as a white solid(1.4g, 72%).

Properties are summarized below.

- 25 M.P. 107-108°C. ¹H NMR (CDCl₃) 7.18 (m, 20H), 6.41 (m, 4H), 5.11 (q, 4H), 3.06 (t, 4H), 2.62 (m, 2H), 1.99 (m, 2H), 1.62 (m, 4H), 1.32 (m, 2H). ¹³C NMR (CDCl₃) 171.8, 171.5, 169.3, 133.9, 133.1, 127.3, 126.5, 124.9, 65.0, 51.1, 42.3, 41.7, 35.7, 25.0, 21.4. Optical Rotation [α]_D²⁴ 20°, (c = 1, CHCl₃). Anal. Calcd. for C₄₀H₄₂N₂O₆: C 74.28, H 6.55, N 4.33, found C 74.40, H 6.53 N 4.35.
- 30

Example 21cis-1,2-bis(N_α-amido-L-phenylalanine) cyclohexane diamide.

The dibenzyl ester from Example 20, (0.97g, 1.5 mmol) and 10% Pd-C (0.15g) were suspended in degassed CH₃OH (100 mL). Hydrogen

5 gas was introduced. TLC (40% EtOAc/ hexane) was used to monitor the reaction. After 2 hours the black suspension was filtered and the filtrate concentrated to provide the diamide diacid as a white crystalline solid (0.70g, 100%).

Properties are summarized below.

10 M.P. 88-90°C. ¹H NMR (DMSO-d₆) 7.82 (m, 2H), 7.18 (m, 10 H), 4.40 (m, 2H), 2.92 (m, 4H), 2.50 (s, 2H), 1.90 (m, 2H), 1.36 (m, 6H). ¹³C NMR (d₆-DMSO) 173.6, 173.1, 172.0, 137.6, 129.1, 128.0, 126.4, 53.3, 42.8, 36.8, 27.1, 26.5, 23.2. Optical Rotation [α]_D²⁴ 33° (c = 1.0, MeOH). Anal. Calcd. for C₂₆H₃₀N₂O₆: C 66.94, H 6.48, N 6.01, Found C 66.72, H 6.53, N 6.05.

15

Example 22atrans-1,4-(bis-N_α-amido-L-phenylalanine-benzyl-ester)-cyclohexane dicarboxylate 22a.

Diphenylphosphoryl azide (DPPA, 6.71g, 24.4 mmol) was added 20 dropwise to a solution of DMF (75 mL), *trans* cyclohexane dicarboxylic acid (2.0g, 11.6 mmol) and L-phenylalanine benzyl ester p-toluenesulfonate salt (10.44g, 24.4 mmol) cooled to 0°C. The mixture was stirred for 15 minutes at 0°C and DIEA (6.60g, 51.1 mmol) was added dropwise over a 5 minute period. The solution was allowed to warm slowly to room temperature and 25 stirred overnight. The volatiles were removed under reduced pressure and the residue dissolved in 150 mL CH₂Cl₂. The cloudy solution was filtered to give a white solid and a yellow filtrate. The solid was washed with EtOAc and dried to give 1.43g of 22a. The filtrate was washed with 1N HCl, water, 10% NaHCO₃ and water. The organic layer was separated, dried, filtered and 30 concentrated to give a yellow solid. Flash column chromatography (3% EtOH/ CHCl₃) gave additional *trans* diamide 22a (4.22g). The total yield of 22a was 5.65g (75%).

Properties are summarized below.

M.P. 211-213°C. ^1H NMR ($\text{d}_6\text{-DMSO}/\text{CDCl}_3$; 3:1) 8.10 (d, 2H, NH), 7.26 (m, 20H), 5.08 (s, 4H), 4.55 (m, 2H), 3.00 (m, 4H), 2.10 (m, 2H), 1.65 (m, 4H), 1.30 (m, 4H). Optical Rotation $[\alpha]_D^{21} 30^\circ$ ($c = 1$, CHCl_3). Anal. Calcd. for $\text{C}_{40}\text{H}_{42}\text{N}_2\text{O}_6$: C 74.28, H 6.55, N 4.33, found 5 C 74.12, H 6.54, N 4.30.

Example 22bcis-1,4-(bis-N σ -amido-L-phenylalanine benzyl ester)
cyclohexane dicarboxylate 22b.

The cis isomer was prepared in a similar manner as its trans 10 counterpart 22a. Column chromatography (5% acetone/ CHCl_3 , $R_f = 0.14$) gave pure 22b (76%).

Properties are summarized below.

M.P. 102-104°C. ^1H NMR (CDCl_3) 7.35 (m, 10H), 7.20 (m, 6H), 7.00 15 (m, 4H), 5.95 (d, 2H), 5.20 (q, 4H), 4.98 (dt, 2H), 3.19 (m, 4H), 2.13 (m, 2H), 1.82 (m, 4H), 1.60 (m, 4H). Optical Rotation $[\alpha]_D^{22} 23^\circ$ ($c = 0.5$, CHCl_3). Anal. Calcd. for $\text{C}_{40}\text{H}_{42}\text{N}_2\text{O}_6$: C 74.28, H 6.55, N 4.33, found C 74.00, H 6.50, N 4.57.

Example 23atrans-1,4-(bis-N σ -L-phenylalanine) cyclohexane
dicarboxylate 23a.

The dibenzyl ester 22a (1.33g, 2.06 mmol) and 10% Pd-C (0.1g) were suspended in absolute EtOH (200 mL). The suspension was degassed three times and hydrogen gas introduced. TLC (4% EtOH/ CHCl_3) showed no starting material remained after 90 minutes at rt. The black 25 suspension was filtered and the filtrate was concentrated to give 23a as a white solid (0.88g, 92%).

Properties are summarized below.

M.P. 249-251°C. ^1H NMR (CD_3OD) 7.21 (m, 10H), 4.64 (dd, 2H, $J^3_{\text{HH}} = 9.3$ Hz, $J^3_{\text{HH}} = 4.9$ Hz), 3.21 (dd, 2H, $J^2 = 13.7$ Hz, $J^3 = 9.5$ Hz), 30 2.13 (m, 2H), 1.80 (d, 2H, $J^3 = 7.55$ Hz), 1.56 (d, 2H, $J^3 = 7.3$ Hz), 1.38 (m, 2H), 1.35 (m, 2H). Optical Rotation $[\alpha]_D^{21} 3^\circ$ ($c = 0.5$, MeOH). Anal. Calcd. for $\text{C}_{26}\text{H}_{30}\text{N}_2\text{O}_6$: C 66.94, H 6.48, N 6.01, found C 66.65, H 6.55, N 5.98.

Example 23bcis-1,4-(bis Na-L-phenylalanine) cyclohexane dicarboxylate 23b.

The cis isomer was prepared in a similar manner as its trans counterpart, compound 23a. The reduction was carried out in degassed

- 5 MeOH and stirred under H₂ for 4 hrs. TLC (10% EtOH/ CHCl₃) was used to monitor the reaction. The suspension was filtered and concentrated to give 23b as a white solid (2.7g, 99%). An analytical sample was obtained by recrystallization from 8% MeOH/ EtOAc.

Properties are summarized below.

- 10 M.P. 185-186°C. ¹H NMR (d₆-DMSO) 7.82 (d, 2H), 7.20 (m, 10H), 4.35 (m, 2H), 3.05 (m, 2H), 2.82 (m, 2H), 2.18 (m, 2H), 1.60 (m, 4H), 1.25 (m, 4H). ¹³C NMR (d₆-DMSO) 174.42, 173.10, 137.72, 128.92, 127.93, 126.16, 52.98, 40.19, 36.57, 26.04, 25.65. FTIR (KBr pellet) 3366, 2953, 1738, 1622, 1539 cm⁻¹. high resolution mass spectrum: (C₂₆H₃₁N₂O₆, M+H) theory 467.2182, found 467.2156. Optical Rotation [α]_D²¹ 26° (c = 1, MeOH). Anal. Calcd. for C₂₆H₃₀N₂O₆: C 66.94, H 6.48, N 6.01, found C 66.79, H 6.51, N 5.94.
- 15

- 20 FTIR data for cis 1,4-(bis Na-L-phenylalanine) cyclohexane dicarboxylic acid.*

SOLVENT*	CONCENTRATION	IR BANDS cm ⁻¹ (area %) ^{b-e}
KBr pellet	3 wt. %	3366(100)
DMSO2	10 mM	3469(70), 3274(30)
25 Acetone	10 mM	3612(47), 3524(20), 3372(33)

a: dried prior to use; b: after subtraction of solvent; c: observed range 3000-4000 cm⁻¹; d: at 300°K; e: percentages were estimated using the width at half height for reported bands.

Variable temperature ^1H NMR of cis 1,4-(bis Na-L-phenylalanine) cyclohexane dicarboxylic acid.*

SOLVENT	Concentration	(ϵ) ^c	ppb/ $^{\circ}\text{K}$ ^d	δ NH (ppm) ^e	Δ ppm ^f
Water ^b	1.1 mM	78.5	-7.4	7.38	0.0 ^f
d_6 -DMSO	10 mM	49	-6.5	7.82	0.30
MeOH	10 mM	32.6	-9.6	7.61	0.26 ^g
d_6 -Acetone	10 mM	20.7	-5.9	6.93	0.35

a:dried prior to use; b: 10% $\text{D}_2\text{O}/\text{H}_2\text{O}$; c: dielectric constants from Gordon, A.J.; Ford, R.A. The Chemist's Companion, New York: John Wiley and Sons 1972, pp. 3-13; d: at 300 $^{\circ}\text{K}$; e: difference of cyclohexyl ring methylene protons at 300 MHz; f: the same sample at 600 MHz gave a 0.03 difference; g: solvent was d^4 -MeOH.

15

Example 24a and 24b - cis- and trans- 1,3 (bis Na-L-phenylalanine benzyl ester) cyclohexane dicarboxylate 24a and 24b.

20 The 1,3 cyclohexane derivatives were prepared in a similar manner as their 1,4 counterparts, i.e. compounds 22a and 22b. Since the starting 1,3 cyclohexane dicarboxylic acid (2.0g, 11.6 mmol) was a mixture of *cis* and *trans* isomers, three isomers were generated in the product mixture of diamides (5.5g, 73%). An analytical sample of the *cis* isomer 24a was 25 isolated by recrystallization from CHCl_3 . A sample of the *trans* diastereomeric mixture 24b was isolated by column chromatography using a trisolvent system (30% EtOAc/ 40% hexane/ 30% CHCl_3 , $R_f = 0.31$) on silica gel.

Properties are summarized below.

30 *cis* 1,3 isomer (24a): M.P. 192-194 $^{\circ}\text{C}$. ^1H NMR (CDCl_3) 7.37 (m, 10H), 7.21 (m, 6H), 6.97 (m, 4H), 5.90 (t, 2H, NH), 5.15 (m, 4H), 4.90 (m, 2H), 3.11 (m, 4H), 2.08 (br t, 2H), 1.95 (d, 1H), 1.80 (m, 3H), 1.55 (q, 1H), 1.29 (m, 3H). Optical Rotation $[\alpha]_D^{28} 30^{\circ}$ ($c = 0.32$, CHCl_3). Anal. Calcd. for $\text{C}_{40}\text{H}_{42}\text{N}_2\text{O}_6$: C 74.28, H 6.55, N 4.33, found C 74.39, H 6.62, N 4.38.

SUBSTITUTE SHEET (RULE 26)

- Diastereomeric mixture of *trans* 1,3 isomers (24b): M.P. 85-88°C. ¹H NMR (CDCl₃) 7.37 (m, 16H), 6.97 (m, 4H), 5.90 (dd, 2H, NH), 5.16 (m, 4H), 4.87 (m, 2H), 3.10 (m, 4H), 2.41 (m, 2H), 1.79 (d, 2H), 1.55 (m, 4H), 1.42 (m, 2H). Optical Rotation [α]_D²⁶ 9° (c = 0.5, CHCl₃).
 5 high resolution mass spectrum for C₄₀H₄₂N₂O₆: theory 646.3043, found 646.3161.

Example 25a - cis- 1,3 (bis N_α-amido-L-phenylalanine) cyclohexane dicarboxylic acid 25a.

- Hydrogenation of 24a (0.69g, 1.07 mmol) over 10% Pd-C
 10 (0.10g) in 100 mL MeOH gave the cis 1,3 diamide diacid 25a as a white solid (0.52g, 100%).

Properties are summarized below.

- M.P. 192-193°C. ¹H NMR (CD₃OD) 7.23 (m, 10H), 4.65 (m, 2H), 3.18 (m, 2H), 2.93 (m, 2H), 2.18 (t, 2H), 1.70 (m, 4H), 1.30 (m, 4H). ¹³C NMR (CD₃OD) 177.93, 177.86, 174.86, 138.53, 138.48, 130.34, 130.33, 129.45, 129.40, 127.82, 127.77, 54.73, 54.68, 45.41, 45.31, 38.45, 38.43, 33.08, 29.92, 29.61, 25.96. Optical Rotation [α]_D²³ 15° (c = 1, MeOH). Anal. Calcd. for C₂₆H₃₀N₂O₆: C 66.94, H 6.48, N 6.01, found C 66.65, H 6.50, N 5.90.
 20

Example 25b - trans 1,3 (bis N_α-amido-L-phenylalanine) cyclohexane dicarboxylic acid 25b.

Hydrogenation of mixture isomers 24b (0.32g, 0.5 mmol) over 10% Pd-C in EtOH gave the diamide diacid isomers 25b as an oil.

- 25 Recrystallization from 50% EtOAc/hexane gave the enhanced 60:40 mixture 25b as a white solid (0.23g, 99%).

Properties are summarized below.

- ¹H NMR (CD₃OD) 7.20 (m, 10H), 4.65 (m, 2H), 3.20 (m, 2H), 2.95 (m, 2H), 2.50 (m, 2H), 1.72 (t, 1H), 1.58 (m, 6H), 1.41 (m, 1H). ¹³C NMR revealed the enhancement of one diastereomer after recrystallization. The 60:40 mixture was used in all assembly experiments. The minor isomer is underlined. ¹³C NMR (CD₃OD) 178.15, 178.13, 175.02, 174.94, 138.67, 138.65, 130.31, 129.45,
 30

129.42, 127.79, 127.75, 58.86, 54.73, 40.64, 40.59, 38.41, 31.22, 30.90, 29.45, 29.32, 22.64, 22.53. Optical Rotation $[\alpha]_D^{24} 5^\circ$ (c = 1, MeOH) high resolution mass spectrum for M + H ($C_{26}H_{31}N_2O_6$): theory 467.2182, found 467.2156.

5

Example 26cis-5-norbornene-endo-2,3-dicarboxy-bis(N-amido-L-Phe-t-butyl ester) 26.

- cis-5-norbornene-endo-2,3-dicarboxylic acid (0.45g, 2.5 mmol) and L-Phe t-butyl ester hydrochloride (1.29g, 5 mmol) were suspended in dry DMF (25 mL) at 0°C. BOP (2.21g, 5 mmol) was added and the suspension stirred for 10 min. DIEA (1.29g, 10 mmol) was added dropwise over 5 min. The reaction now clear was allowed to warm to room temperature and stirred overnight. The volatiles were removed under reduced pressure and the residue dissolved in EtOAc, washed successively with 10% aq. NaHCO₃, H₂O, 0.5N HCl, and water. The organic layer was separated, dried over anhydrous MgSO₄, filtered and concentrated. Column chromatography (40% EtOAc/ hexane) gave the bis amide 26 (1.11g, 75%).

Properties are summarized below.

- M.P. 116-118°C. ¹H NMR (CDCl₃) 7.30 (m, 6H), 7.20 (m, 4H), 6.32 (d, 2H), 6.20 (m, 1H), 6.10 (m, 1H), 4.60 (m, 2H), 3.25 (s, 2H), 3.10 (m, 6H), 1.41 (s, 9H), 1.40 (s, 9H), 1.39 (m, 2H). Optical Rotation $[\alpha]_D^{24} 11^\circ$ (c = 1, MeOH). Anal. Calcd. for C₃₅H₄₄N₂O₆: C 71.40, H 7.53, N 4.76, found C 71.29, H 7.51, N 4.70.

25 Example 27cis-5-norbornene-endo-2,3-dicarboxy-bis(N-amido-L-Phe-t-butyl ester) 27.

- The norbornene (0.45g, 0.76 mmol) was dissolved in MeOH (50 mL) and 10% Pd-C (0.05g) was added. The black suspension was degassed three times and hydrogen gas was introduced. The reaction was complete after 30 minutes (TLC) and the reaction was filtered. The filtrate was concentrated to provide the norbornene as a white solid (0.44g, 98%).

Properties are summarized below.

- M.P. 137-138°C. ^1H NMR (CDCl_3) 7.06 (m, 10H), 6.21 (m, 2H), 4.57 (m, 2H), 2.89 (m, 4H), 2.63 (m, 2H), 2.24 (m, 2H), 1.66 (m, 4H), 1.21 (m, 18H). ^{13}C NMR (CDCl_3) 171.3, 170.8, 136.5, 129.7, 128.1, 126.7, 82.1, 53.6, 48.6, 41.1, 40.7, 40.3, 38.1, 37.8, 24.1. Anal.
 5. Calcd. for $\text{C}_{35}\text{H}_{46}\text{N}_2\text{O}_6$: C 71.16, H 7.85, N 4.74, found C 70.95, H 7.88, N 4.65.

Example 28 - cis-5-norbornene-endo-2,3-dicarboxy-bis(N-amido-L-Phe) 28.

10 The bis t-butyl ester (0.59g, 1 mmol) was dissolved in TFA (10 mL) at 0°C. The reaction was monitored by TLC and was complete in 1 hr. The volatiles were removed under reduced pressure to give an oil which was diluted in 30% EtOAc/hexane to give a solid. The solid was filtered off and recrystallized from 30% MeOH-diethyl ether to give the diacid 28 as a white
 15 solid (0.4g, 84%).

Properties are summarized below.

M.P. 206-207°C. ^1H NMR (d_6 -DMSO) 12.25 (br, 2H), 7.68 (m, 2H), 7.23 (m, 10H), 5.97 (m, 1H), 5.53 (m, 1H), 4.39 (m, 1H), 4.30 (m, 1H), 3.13 (m, 2H), 2.88 (m, 6H), 1.16 (m, 2H). ^{13}C NMR (d_6 -DMSO)
 20 172.9, 172.8, 171.7, 170.9, 137.6, 137.4, 135.2, 133.4, 129.3, 129.2, 129.1, 128.1, 126.3, 126.2, 53.6, 53.0, 49.3, 49.1, 48.1, 47.1, 46.3, 37.1, 36.8. Optical Rotation $[\alpha]_D^{23}$ 42° (c = 1, MeOH).
 Anal. Calcd. for $\text{C}_{27}\text{H}_{28}\text{N}_2\text{O}_6$: C 68.05, H 5.92, N 5.88, found C 67.81, H 6.11, N 5.80.

25

Example 29 - cis-5-norbornane-endo-2,3-dicarboxy-bis(N-amido-L-Phe) 29.

The norbornyl bis t-butyl ester (0.37g, 0.63 mmol) was dissolved in TFA (5 mL) at 0°C. The reaction was monitored by TLC and was
 30 complete in 1 hr. The volatile material was removed under reduced pressure to give a solid. The solid was filtered and washed with diethyl ether to give the diacid 29 as a white solid (0.25g, 83%).

Properties are summarized below.

M.P. 200-201°C. ^1H NMR (d_6 -DMSO) 12.50 (br, 2H), 7.87 (m, 1H), 7.67 (m, 1H), 7.18 (m, 10H), 4.46 (m, 1H), 4.36 (m, 1H), 2.84 (m, 8H), 2.28 (m, 2H), 1.12 (m, 4H). ^{13}C NMR (d_6 -DMSO) 173.04, 173.01, 171.7, 171.1, 137.6, 137.5, 129.2, 129.1, 128.0, 126.2, 53.3, 53.0, 46.8, 46.5, 41.2, 40.1, 37.3, 36.9, 23.8, 23.0. Optical Rotation $[\alpha]_D^{23}$ 45° (c = 1, MeOH). Anal. Calcd. for $\text{C}_{27}\text{H}_{30}\text{N}_2\text{O}_6$: C 67.77, H 6.32, N 5.85, found C 67.52, H 6.37, N 5.80.

Microsphere Formation

10 Example 30 - Microspheres

The bis-amide dicarboxylic acid prepared according to the method of Example 4 was dissolved in 0.1 mL of aqueous Li_2CO_3 (0.1M) to yield a clear solution of the lithium salt in deionized water. 50 μL of the 0.1M solution was mixed with 50 μL of 1M aqueous citric acid and shaken.

15 A white suspension was generated. Microscopic examination of the suspension revealed the formation of tiny spheres having diameters from 10 μm to submicrons.

Example 31 - Microspheres

20 The method of Example 30 was followed, substituting the bis-amide dicarboxylic acid prepared according to the method of Example 5. A white suspension was generated. Microscopic examination of the suspension revealed the formation of tiny spheres having diameters from 10 μm to submicrons.

25

Example 32 - Microspheres

The method of Example 30 was followed, substituting the bis-amide dicarboxylic acid prepared according to the method of Example 6. A white suspension was generated. Microscopic examination of the suspension revealed the formation of tiny spheres having diameters from 10 μm to submicrons.

The sodium salt of the bis-amide dicarboxylic acid of Example 6 was prepared. A white suspension was prepared by combining 100 μL of

0.43M citric acid and 50 μ L of a 0.1M aqueous solution of the sodium salt of the diamide. The aqueous suspension was deposited on polylysine-coated glass coverslips and fixed with 2% OsO₄ for 4 hours. The sample was washed with distilled water, air dried and sputter coated with gold. SEM 5 photographs are illustrated in Figures 5a and 5b. SEM photographs of compound 23b were prepared in a similar manner and are illustrated in Figures 5c and 5d.

A white suspension was also prepared by adding a solution containing 50 μ L of a 0.86M citric acid and 50 μ L of 3 wt. % tannic acid to 10 50 μ L of a 100 mM aqueous solution of the sodium salt of the diamide. The pH was lowered from 7.7 to 2.4. The aqueous solution was deposited on a Nucleopore filter and fixed with 4% OsO₄ for 4 hours. The sample was washed with distilled water and 95% EtOH and was air dried. The sample was dispersed in 100% LR white resin and polymerized in an oven at 60°C. 15 TEM photographs are illustrated in Figure 6.

Estimates of the microcapsule shell thickness (150 nm) would require approximately 100 molecules of the diamide of Example 6 oriented end-to-end to traverse the microcapsule shell. However, a stacking of the bis amides seems more likely. A stacked array would allow for a greater number 20 of assembled tetrapeptides to traverse the capsule shell. It is notable that the self-recognition of fragments of the bis-amide dicarboxylic acid of Example 6 must be energetically favorable enough during the assembly process, that the presence of the tannic acid does not interfere with the formation of microcapsules. Little tannic acid was incorporated into the 25 microsphere shell. However, some tannic acid may be intercalated in the microsphere wall. Nevertheless, the presence of tannic acid does not disrupt the formation of microcapsules.

Example 33 - Microspheres

30 The method of Example 30 was followed, substituting the bis-amide dicarboxylic acid prepared according to the method of Example 15. A white suspension was generated. Microscopic examination of the suspension

revealed the formation of tiny spheres having diameters from 10 μm to submicrons.

Example 34 Microspheres

5

The method of Example 17 was followed, substituting the bis-amide dicarboxylic acids prepared according to the method of Examples 20, 22b, and 24b. A white suspension was generated. Microscopic examination of the suspension revealed the formation of tiny spheres having diameters from 10 μm to submicrons.

10



Attempts to prepare microspheres with the bis-amide dicarboxylic acids from Examples 18a, 18b, 23a, 25a, 28, and 29, however these attempts were unsuccessful.

Results are illustrated in Table 1

TABLE 1

15

MICROSPHERE FORMATION



	<u>Compound</u>	<u>Diacid Platform</u>	<u>est. ϕ value</u>	<u>dihedral angle α</u>	<u>Results</u>
20	18a,b	trans 1,2 cyclohexane		45°	crystalline ppt.
	21	cis 1,2 cyclohexane		40°	microspheres
	25a	cis 1,3 cyclohexane	130°		amorphous ppt.
	25b	trans 1,3 cyclohexane	106°		microspheres
	23b	cis 1,4 cyclohexane	115°		microspheres
	23a	trans 1,4 cyclohexane	179°		amorphous ppt.
25	28	endo 2,3 norbornene	56°	7°	amorphous ppt.
	29	endo 2,3 norbornane	65°	2°	amorphous ppt.

The impact of the bond distance between Phe amides upon microsphere self-assembly is noticed when comparing the diamide-dicarboxylic acid series L-PheCO-(CH₂)_n-COL-Phe (with n = 0, 1, and 2), as only the compound of Example 4 (where n = 1) generated microcapsules 5 under the conditions in the Examples above while neither the oxalic derivative of Example 8 nor the succinic analogue of Example 12 did. These results further support the importance of the *cis* relationship between the two Phe groups for self assembly.

Additionally, the compounds above which self-assembled into 10 microspheres all had a critical angle (ϕ) in their diacid platform, which oriented the Phe fragments towards each other. This angle was fixed. The compounds of Examples 4-6 (with $\phi_a = 118^\circ$, $\phi_s = 110^\circ$, $\phi_b = 106^\circ$, respectively) and Examples 23b, and 25b (with $\phi = 115^\circ$ and $\phi = 106^\circ$, respectively) orient the Phe pendants towards each other with a locked geometry 15 imparted by the tetrahedral carbon spacer.

The lack of a fixed spatial orientation of the Phe pendants in the compound of Example 12 can be used to explain why this compound does not self assemble under the conditions above, even though it possesses sufficient tether length and conformational flexibility. This requirement of 20 having a rigid *cis* orientation is further illustrated with the maleic and fumaric acid platforms. The malic acid-bis Phe conjugate of Example 15 ($\phi = 60^\circ$) generated microcapsules, whereas the isomeric fumaric derivative of Example 16 ($\phi = 180^\circ$) did not. These platforms are unique in that they approximate the eclipsed Phe and anti-Phe rotamers of the compound of Example 12. The 25 fact that the maleic construct of Example 15 ($\phi = 60^\circ$) formed microspheres under the conditions described above further underscores the importance of attaining a fixed *cis* geometry.

Example 35 - Concentration Dependence

30 A stock solution containing the lithium salt of the diamide prepared according to the method of Example 4 was prepared by stepwise addition of exactly two equivalents of a standardized solution of LiOH (stored under argon to prevent precipitation of lithium carbonate). The final

concentration of the dilithium salt of the diamine was 100 mM, and the pH was always between 7.0 and 8.0. The solution was filtered through a 0.2 μ m membrane prior to use. An appropriate amount of the 100 mM stock solution was diluted with deionized water to 500 μ L. Microsphere formation

- 5 was then initiated by addition of an equal volume of 1 M citric acid, so that the final concentration ranged from 0 to 50 mM dilithium diamide in 500 mM citric acid with the pH below 2.5. Turbidity was assessed over this range of concentrations by measuring % transmittance at 600 nm.

Results are illustrated in Figures 7 and 8 and tabulated in Table 2
10 below.

Example 36 - Concentration Dependence

The method of Example 30 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 5.

- 15 Results are illustrated in Table 2.

Example 37 - Concentration Dependence

The method of Example 35 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 6.

- 20 Results are illustrated in Table 2.

Example 38 - Concentration Dependence

The method of Example 35 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 15.

- 25 Results are illustrated in Table 2.

Example 39 - Concentration Dependence

The method of Example 35 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 21.

- 30 Results are illustrated in Table 2.

Example 40 - Concentration Dependence

The method of Example 35 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 23b.

Results are illustrated in Table 2.

5

Example 41 - Concentration Dependence

The method of Example 35 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 25b.

Results are illustrated in Table 2.

10

Example 42 - pH Dependence

500 μ L of 100 mM dilithium diamide solution prepared according to the method of Example 21 was mixed with an equal volume of one of a series of 1 M lithium citrate buffers containing between 0 to 1 equivalent of lithium hydroxide so that the final measured pH of the mixture ranged from ca. 2.4 to 4.0. Turbidity was assessed over this pH range by measuring % transmittance at 600 nm.

Results are illustrated in Figures 9 and 10 and tabulated in Table 2.

20

Example 43 - pH Dependence

The method of Example 42 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 5.

Results are illustrated in Table 2.

25

Example 44 - pH Dependence

The method of Example 42 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 6.

Results are illustrated in Table 2.

30

Example 45 - pH Dependence

The method of Example 42 was followed substituting the bis-amide dicarboxylic acid prepared according to the method of Example 15.

Results are illustrated in Table 2.

Example 46 - pH Dependence

- The method of Example 42 was followed substituting the bis-
 5 amide dicarboxylic acid prepared according to the method of Example 21.
 Results are illustrated in Table 2.

Example 47 - pH Dependence

- The method of Example 42 was followed substituting the bis-
 10 amide dicarboxylic acid prepared according to the method of Example 23b.
 Results are illustrated in Table 2.

Example 48 - pH Dependence

- The method of Example 42 was followed substituting the bis-
 15 amide dicarboxylic acid prepared according to the method of Example 25b.
 Results are illustrated in Table 2.

20

Table 2
Concentration, pH and pKa Parameters

Example	Concentration (mM)*	pH**	pKa1	pKa2
35,42	30	3.26	3.67	4.70
36,43	25	3.26	3.55	4.62
37,44	13	3.26	3.53	4.50
25	38,45	3.26	3.70	4.87
	39,46	3.26	3.71	4.83
	40,47	3.26	3.65	4.63
	41,48	3.26	3.63	4.59

30

- * concentration of amide above which a dense suspension (%T < 0.5) of microspheres is formed in the presence of 500 mM citric acid (pH 2.4).

Each of the compounds of Examples 4-6, 15, 21, 23b, and 25b was evaluated by monitoring the change in the solution turbidity, while altering the pH at a fixed Phe amide concentration or by holding the pH constant and varying the concentration of the amide substrate. Each

- 5 concentration dependence was determined in 500 mM citric acid from a plot of the solution transmittance (%T) vs. concentration. For example, the compound of Example 4 demonstrated a sharp transition from a clear solution (>95% T) to a dense suspension of microcapsules (0.2% T) at concentrations of diamide above 30 mM. The influence of pH on solution
10 turbidity was studied in solutions containing 50 mM in 500 mM lithium citrate buffers. The percent transmittance (%T) was <0.5% at pH 2.67 and >95% at pH 3.26. The pKas were determined by titration of each Phe amide substrate. As expected, the pKas of these Phe diamide diacids were all very similar.

- 15 The experimental data are consistent with multiple factors contributing to assembly. Protonation of the carboxylate anion is a factor. However, the bisamide data suggests that orientation in space, and hence alignment and maintenance of that alignment with its nearest neighbors, are also important factors. The maintenance of this alignment is effected
20 through a combination of non-covalent interactions between any given molecule and its nearest neighbors. Thus, while protonation of the carboxylate anion can certainly effect solubility, it contributes towards assembly by impacting on hydrogen bonding to its nearest neighbor.

- The experimental data are also consistent with the likelihood of
25 pre-assembly of microspheres in solution prior to precipitation by the addition of precipitator. If assembly were simply a phase change phenomenon, then given the unfavorable thermodynamics of an apparent decrease in entropy inherent in the assembly process it would be difficult to explain how protonation of the carboxylate anion would provide a sufficient enthalpic
30 contribution to overcome the entropic effects. Without being bound by any theory, it is believed that it is more likely that through a collection of non-covalent interactions between nearest neighbors i.e. hydrogen bonding, vander Waals forces, hydrophobic interactions, etc., a sufficiently large

potential energy well is created that can stabilize and maintain the preassembled state. This state is comparable to the critical micellar concentration (CMC) exhibited by liposomal preparations. Hence, the observed concentration and steric effects on assembly.

5 It is possible that the carboxylate anions actually hinder self-assembly by the electrostatic repulsion of like charges. From our pKa and pH measurements we estimate that one anionic species per 30 molecules of the diamide of Example 4 might be sufficient to abort assembly.

10 However, if protonation were the only important parameter, substrates with similar pKa's would demonstrate the same pH and concentration dependence. This is certainly true for the pH dependence of the microsphere-forming substrates of Examples 4-6, 15, 21, 23b, and 25b as each generates microspheres at a pH well below their measured pKa's. However, the compounds show different concentration dependencies

15 (Example 6: 13 mM vs. Example 4: 30 mM).

The diamide-dicarboxylic acids of Examples 4-6, 15, 21, 23b, and 25b formed helical structures with their carboxyl groups oriented away from the hydrophobic central core. Helical conformations for the diamide-dicarboxylic acids of Examples 4 and 15 are illustrated in the BIOSYM

20 generated structures in Figures 11A and 11B, respectively.

Dynamic studies of these conformations showed other conformations which were close in energy to those predicted. These alternate structures were also helical and have one seven membered H-bond between the terminal carboxyls and the carboxyls of the Phe amide. By

25 locking in a cis geometry, the scaffolds allow these diacids to complete the helical turn necessary for the generation of the hydrophobic helix. (The term "cis" is used to describe a configuration in which the Phe pendants are oriented towards each other). Without being bound by any theory, it is believed that the acidification of the terminal carboxylates allow for

30 intermolecular hydrogen bonding (between different helical subunits), thereby generating larger arrays as illustrated in Figure 13. This is consistent with the observation that anionic species (R-COO⁻, a non-H-bond donor) can disrupt the assembly process.

The diacids of Examples 8, 11, 12, 16, 18 23a, 25a, 28, and 29 did not form microspheres under the conditions of the present examples and gave the linear and pocket-like structures illustrated in Figures 14, B, and C.

5 This increased distance allows the amide groups to twist slightly out of the conjugation plane to accommodate a seven membered H-bond with the terminal COOH. Due to the flexible CH₂CH₂ spacer of the succinic derivative of Example 12, one may have expected it to adopt a conformation which was similar to the fumarate derivative of Example 16 or its maleic
10 counterpart of Example 15. However, each of these conformations would require the diacid of Example 12 to adopt a higher energy eclipsed conformer. The succinic moiety of the diacid of Example 12 adopted a pocket structure with the phenyl rings pointed away from each other. The flexible ethyl spacer of the diacid of Example 12 prefers a staggered conformation and
15 contributes to the formation of a pocket geometry. It is possible that these conformations may be significantly altered during the assembly of two or more species in an aqueous environment.

The above Examples indicate several structural criteria that low molecular weight diamides should possess in order to undergo microsphere
20 self-assembly under the conditions described herein. First, there should be a certain tether length between the amino acid pendants in order to attain the required geometry for molecular packing. Second, the di-acid platform should orient the amino acid subunits with a certain angle ϕ (e.g. between 60° and 120°). Third, this angle should be fixed in space. Substrates having a *cis*
25 geometry appear to undergo this type of self-assembly. This spatial orientation can be attained either through reduced conformational flexibility (with rings or *cis* double bonds) or by using other fixed geometries imparted by the diacid platform itself (for example, the tetrahedral geometry imparted by the central sp³ hybridized carbon of the compound of Example 4. The
30 Examples are consistent with the idea that molecules that undergo assembly into microspheric geometrics preferably possess critical tether distances with a fixed angular orientation ($\phi = 60$ to 120°) of amino acid subunits.


All patents, applications, test methods, and publications mentioned herein are hereby incorporated by reference.

Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. All such 5 obvious variations are within the full intended scope of the appended claims.

IN THE CLAIMS:

- 1 1. A microsphere comprising at least one diamide-**

2 dicarboxylic acid having the formula



6 wherein:

7 R is C₁-C₂₄ alkyl, C₁-C₂₄ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cyclo-
8 alkenyl, phenyl, naphthyl, (C₁-C₁₀ alkyl) phenyl, (C₁-C₁₀ alkenyl) phenyl, (C₁-
9 C₁₀ alkyl) naphthyl, (C₁-C₁₀ alkenyl) naphthyl, phenyl (C₁-C₁₀ alkyl), phenyl
10 (C₁-C₁₀ alkenyl), naphthyl (C₁-C₁₀ alkyl), or naphthyl (C₁-C₁₀ alkenyl);
11 optionally R may be substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl,
12 C₁-C₄ alkoxy, -OH, -SH, -CO₂R¹, or any combination thereof;
13 R¹ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkenyl; R is optionally
14 interrupted
15 by oxygen, nitrogen, sulfur, or any combination thereof;
16 n is 0 or 1; and
17 A and B independently are an amino acid radical or a poly amino
18 acid radical;
19 an ester thereof, a diester thereof, or any combination of any of
20 the foregoing.

**2. A composition as defined in claim 1, wherein said
microsphere comprises a microcapsule.**

1 3. A composition as defined in claim 1, wherein said
2 microsphere has a diameter of less than 10 microns.


1 4. A composition as defined in claim 1, wherein A, B, or A
2 and B comprises an amino acid radical.

1 5. A composition as defined in claim 4, wherein said amino
 2 acid radical is selected from the group consisting of radicals of naturally
 3 occurring amino acids and radicals of non-naturally occurring amino acids.

1 6. A composition as defined in claim 1, wherein A, B, or A
 2 and B comprise a poly amino acid radical.

1 7. A composition as defined in claim 6, wherein said poly
 2 amino acid radical comprises an amino acid radical selected from the group
 3 consisting of radicals of naturally occurring amino acids, radicals of non-
 4 naturally occurring amino acids, or combinations thereof.

1 8. A composition comprising
 2 (a) an active agent, and
 3 (b) at least one diamide-dicarboxylic acid having the formula



7 wherein:

8 R is C₁-C₂₄ alkyl, C₁-C₂₄ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cyclo-
 9 alkenyl, phenyl, naphthyl, (C₁-C₁₀ alkyl) phenyl, (C₁-C₁₀ alkenyl) phenyl, (C₁-
 10 C₁₀ alkyl) naphthyl, (C₁-C₁₀ alkenyl) naphthyl, phenyl (C₁-C₁₀ alkyl), phenyl
 11 (C₁-C₁₀ alkenyl), naphthyl (C₁-C₁₀ alkyl), or naphthyl (C₁-C₁₀ alkenyl);

12 optionally R may be substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl,
 13 C₁-C₄ alkoxy, -OH, -SH, -CO₂R¹, or any combination thereof;

14 R¹ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkenyl; R is optionally
 15 interrupted by oxygen, nitrogen, sulfur, or any combination thereof;

16 n is 0 or 1; and

17 A and B independently are an amino acid radical or a poly amino
 18 acid radical; an ester thereof, a diester thereof, or any combination of any of
 19 the foregoing.

1 **9. A composition as defined in claim 8, comprising a**
2 **microsphere.**

1 **10. A composition as defined in claim 9, wherein said**
2 **microsphere comprises a microcapsule.**

1 **11. A composition as defined in claim 9, wherein said**
2 **microsphere has a diameter of less than 10 microns.**

1 **12. A composition as defined in claim 8, wherein said active**
2 **agent comprises an agent selected from the group consisting of biologically**
3 **active agents and chemically active agents.**

1 **13. A composition as defined in claim 12, wherein said active**
2 **agent comprises a biologically active agent.**

1 **14. A composition as defined in claim 12, wherein said active**
2 **agent comprises a chemically active agent.**

1 **15. A composition as defined in claim 8, wherein said active**
2 **agent is selected from the group consisting of a peptide, a**
3 **mucopolysaccharide, a carbohydrate, a lipid, a pesticide, a fragrance, a**
4 **cosmetic, or any combination thereof.**

1 **16. A composition as defined in claim 15, wherein said active**
2 **agent is selected from the group consisting of human growth hormone,**
3 **bovine growth hormone, growth hormone-releasing hormone, an interferon,**
4 **interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial natriuretic factor,**
5 **an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin,**
6 **gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium,**
7 **vancomycin, desferrioxamine (DFO), or any combination of any of the**
8 **foregoing.**

1 **17. A composition as defined in claim 8, wherein A, B, or A**
2 **and B comprises an amino acid.**

1 **18. A composition as defined in claim 17, wherein said amino**
2 **acid radical is selected from the group consisting of radicals of naturally**
3 **occurring amino acids and radicals of non-naturally occurring amino acids.**

1 **19. A composition as defined in claim 8, wherein A, B, or A**
2 **and B comprise a poly amino acid radical.**

1 **20. A composition as defined in claim 19, wherein said poly**
2 **amino acid radical comprises an amino acid radical selected from the group**
3 **consisting of radicals of naturally occurring amino acids, radicals of non-**
4 **naturally occurring amino acids, or combinations thereof.**

1 **21. A composition as defined in claim 8, further comprising:**
2 **(c) at least one enzyme inhibitor.**

1 **22. A dosage unit form comprising**
2 **(A) a composition as defined in claim 8, and**
3 **(B) (a) an excipient,**
4 **(b) a diluent,**
5 **(c) a disintegrant,**
6 **(d) a lubricant,**
7 **(e) a plasticizer,**
8 **(f) a colorant,**
9 **(g) a dosing vehicle, or**
10 **(h) any combination thereof.**

1 **23. A method for imaging a portion of the body of an animal,**
2 **said method comprising**
3 **(A) introducing at least one microsphere as defined in**
4 **claim 1 into said portion of said body, and**


5 (B) imaging said portion of said body.

1 24. A method as defined in claim 23, wherein said
2 microsphere is introduced by oral administration.

1 25. A method as defined in claim 23, wherein said imaging is
2 performed by ultrasound.

1 26. A method for administering an active agent to an animal in
2 need of such agent, said method comprising administering orally to said
3 animal, at least one microsphere as defined in claim 8.

1 27. A method for preparing microspheres, said method
2 comprising
3 (A) solubilizing, in a solvent, at least one diamide-
4 dicarboxylic acid having the formula



8 wherein:

9 R is C₁-C₂₄ alkyl, C₁-C₂₄ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cyclo-
10 alkenyl, phenyl, naphthyl, (C₁-C₁₀ alkyl) phenyl, (C₁-C₁₀ alkenyl) phenyl, (C₁-
11 C₁₀ alkyl) naphthyl, (C₁-C₁₀ alkenyl) naphthyl, phenyl (C₁-C₁₀ alkyl), phenyl
12 (C₁-C₁₀ alkenyl), naphthyl (C₁-C₁₀ alkyl), or naphthyl (C₁-C₁₀ alkenyl);

13 optionally R may be substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl,
14 C₁-C₄ alkoxy, -OH, -SH, -CO₂R¹, or any combination thereof;


15 R¹ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkenyl; R is optionally
16 interrupted by oxygen, nitrogen, sulfur, or any combination thereof;

17 n is 0 or 1; and

18 A and B independently are an amino acid radical or a poly amino
19 acid radical;

- 20 an ester thereof, a diester thereof, or any combination of any of
 21 the foregoing to yield a first solution; and
 22 (B) contacting said first solution with a precipitator
 23 solution in which said diamide-dicarboxylic is insoluble.

- 1 28. A method for preparing microspheres containing an active
 2 agent, said method comprising:
 3 (A) solubilizing, in a solvent, at least one diamide-dicarboxylic
 4 acid having the formula



8 wherein:

9 R is C₁-C₂₄ alkyl, C₁-C₂₄ alkenyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cyclo-
 10 alkenyl, phenyl, naphthyl, (C₁-C₁₀ alkyl) phenyl, (C₁-C₁₀ alkenyl) phenyl, (C₁-
 11 C₁₀ alkyl) naphthyl, (C₁-C₁₀ alkenyl) naphthyl, phenyl (C₁-C₁₀ alkyl), phenyl
 12 (C₁-C₁₀ alkenyl), naphthyl (C₁-C₁₀ alkyl), or naphthyl (C₁-C₁₀ alkenyl);
 13 optionally R may be substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl,
 14 C₁-C₄ alkoxy, -OH, -SH, -CO₂R¹, or any combination thereof;

15 R¹ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkenyl; R is optionally
 16 interrupted by oxygen, nitrogen, sulfur, or any combination thereof;

17 n is 0 or 1; and


18 A and B independently are an amino acid radical or a poly amino
 19 acid radical;

20 an ester thereof, a diester thereof, or any combination of any of
 21 the foregoing to yield a first solution; and

22 (B) contacting said first solution with said active agent and a
 23 precipitator solution in which said diamide-dicarboxylic acid is insoluble.

- 1
 2 29. A microsphere comprising at least one diamide-
 dicarboxylic acid having the formula

3
4
5



6 wherein:

7 R is C₁-C₂₄ alkyl, C₁-C₂₄ alkenyl, phenyl, naphthyl, (C₁-C₁₀ alkyl)

8 phenyl, (C₁-C₁₀ alkenyl) phenyl, (C₁-C₁₀ alkyl) naphthyl, (C₁-C₁₀ alkenyl)

9 naphthyl, phenyl (C₁-C₁₀ alkyl), phenyl (C₁-C₁₀ alkenyl), naphthyl (C₁-C₁₀

10 alkyl), or naphthyl (C₁-C₁₀ alkenyl);

11 optionally R may be substituted with C₁-C₄ alkyl, C₁-C₄ alkenyl,

12 C₁-C₄ alkoxy, -OH, -SH, -CO₂R¹, or any combination thereof;

13 R¹ is hydrogen, C₁-C₄ alkyl or C₁-C₄ alkenyl; R is optionally

14 interrupted by oxygen, nitrogen, sulfur, or any combination thereof;

15 n is 0 or 1; and

16 A and B independently are an amino acid radical or a poly amino


17 acid radical;

18 an ester thereof, a diester thereof, or any combination of any of

19 the foregoing.

1/21

FIG. I



Example 4: $R = H$, $R_2 = Bn = Cl$


Example 5: $R = \text{CH}_3$, $R_2 = \text{Bn}$, $X = \text{ONHS}$

Example 6: R = cyclo CH_2 , R₂ = t-Bu, X = ONHS

SUBSTITUTE SHEET (RULE 26)

2 / 21



FIG. 2



SUBSTITUTE SHEET (RULE 26)


3/21

FIG. 3



Example 17a,b = 1, 2 -trans
 Example 22a = 1, 4, -trans
 Example 22b = 1, 4, -cis
 Example 24a = 1, 3 -cis
 Example 24b = 1, 3 -trans

H₂/10% Pd-C




Example 18a,b = 1, 2 -trans
 Example 25a = 1, 3, -cis
 Example 25b = 1, 3, -trans
 Example 23b = 1, 4 -cis
 Example 23a = 1, 4 -trans

SUBSTITUTE SHEET (RULE 26)

4/21

FIG. 4



Example 21 : 1, 2 cis

SUBSTITUTE SHEET (RULE 26)

5/21


FIG. 5A




004253 8.0 kV X6.00K 3.00 μ m

SUBSTITUTE SHEET (RULE 26)

6/21

FIG. 5B

004219 8.0 kV x1.50K 12.0 μm


FIG. 5C

008153 6.0 kV x18.0K 1.00 μm

SUBSTITUTE SHEET (RULE 26)

7/21

FIG. 5D



Specimen 413 5.0 kV x4.50K 4.00μm

SUBSTITUTE SHEET (RULE 26)

8/21


FIG. 6



SUBSTITUTE SHEET (RULE 26)

9/21


FIG. 7



SUBSTITUTE SHEET (RULE 26)

10/21


FIG. 8



SUBSTITUTE SHEET (RULE 26)

11/21


FIG. 9



SUBSTITUTE SHEET (RULE 26)

12 / 21

FIG. 10



SUBSTITUTE SHEET (RULE 26)

13/21

FIG. II A






FIG. II B



RECTIFIED SHEET (RULE 91)

14/21


FIG. 12



RECTIFIED SHEET (RULE 91)

15/21

FIG. 13



RECTIFIED SHEET (RULE 91)

16/21

FIG. 14B






FIG. 14A



RECTIFIED SHEET (RULE 91)

17/21


FIG. 14C



RECTIFIED SHEET (RULE 91)

18/21


FIG. 15A



RECTIFIED SHEET (RULE 91)

19/21

FIG. 15B



RECTIFIED SHEET (RULE 91)

20/21





FIG. 15C

RECTIFIED SHEET (RULE 91)

21/21

FIG. 16



RECTIFIED SHEET (RULE 91)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/06502

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/16, 47/12, 47
US CL : 424/489

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/489

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,837,381 (STEBER ET AL.) 06 June 1989.	1-29

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
- *T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *A document defining the general state of the art which is not considered to be of particular relevance
- *X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *E earlier document published on or after the international filing date
- *Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O document referring to an oral disclosure, use, exhibition or other means
- *P document published prior to the international filing date but later than the priority date claimed
- *& document member of the same patent family

Date of the actual completion of the international search

23 JULY 1996

Date of mailing of the international search report

07 AUG 1996

Name and mailing address of the ISA/US
Commissioner of Patents and TrademarksBox PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EDWARD J. WEBMAN

Telephone No. (703) 308-2351